<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5297-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ABSTRAL 100MCG SUBLINGUAL TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENTANYL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Sublingual use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Sublingual tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        271.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RECIPHARM PARETS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RECIPHARM PARETS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            KYOWA KIRIN LIMITED 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Abstral<em> </em>is a treatment for adults <strong>wh</strong><strong>o</strong><strong> mus</strong><strong>t</strong><strong> alread</strong><strong>y</strong><strong> regularl</strong><strong>y</strong><strong> be takin</strong><strong>g</strong><strong> stro</strong><strong>n</strong><strong>g pai</strong><strong>n</strong><strong>-re</strong><strong>l</strong><strong>ieving</strong><strong> </strong><strong>medicine </strong><strong>(</strong><strong>opioi</strong><strong>d</strong><strong>s) </strong>for their persistent cancer pain, but require treatment for their breakthrough pain. &nbsp;If you are not sure, talk to your doctor.&nbsp;</p><p>&nbsp;</p><p>Breakthrough pain is pain which occurs suddenly, even though you have taken or used your usual opioid pain-relieving medicine.</p><p>&nbsp;</p><p>The active substance in Abstral sublingual tablets is fentanyl. &nbsp;Fentanyl belongs to a group of strong pain-relieving medicines called opioids.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not</strong><strong> </strong><strong>take</strong><strong> </strong><strong>Abstral</strong></p><p>&nbsp;</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>if you are allergic to fentanyl or any of the other ingredients of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are not regularly using a prescribed opioid medicine (e.g codeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine), every day on a regular schedule, for at least a week, to control your persistent pain. If you have not been using these medicines you <strong>must not</strong> use Abstral because it may increase the risk that breathing could become dangerously slow and/or shallow, or even stop</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from short-term pain other than breakthrough pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being treated with medicines containing sodium oxybate</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before taking Abstral if you have or have recently had any of the following, as your doctor will need to take account of these when prescribing your dose:</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>a head injury, because Abstral may cover up the extent of the injury</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>breathing problems or suffer from myasthenia gravis (a condition characterised by muscle weakness)</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>if you have<strong> </strong>problems with your heart, especially a slow heart rate &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver or kidney disease, as this may require your doctor to more carefully adjust your dose</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>a brain tumour and/or raised intracranial pressure (an increase of pressure in the brain which causes severe headache, nausea/vomiting and blurred vision)</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>mouth wounds or mucositis (swelling and redness of the inside of the mouth)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you take antidepressants or antipsychotics please refer to the section &lsquo;Other medicines and Abstral&rsquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever developed adrenal insufficiency or lack of sex hormones (androgen deficiency) with opioid use</p><p>&nbsp;</p><p>When taking Abstral, inform your doctor or dentist that you are taking this medicine, if:</p><ul><li>you are to have any surgery</li><li>you experience pain or increased sensitivity to pain (hyperalgesia) which does not respond to a higher dosage of your medicine as prescribed by your doctor</li><li>you experience a combination of the following symptoms: nausea, vomiting, anorexia, fatigue, weakness, dizziness and low blood pressure. Together these symptoms may be a sign of a potentially life-threatening condition called adrenal insufficiency, a condition in which the adrenal glands do not produce enough hormones</li></ul><p>&nbsp;</p><p>Your doctor may need to check you more closely if:</p><ul><li>you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs (&ldquo;addiction&rdquo;)</li><li>you are a smoker</li><li>you have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses</li></ul><p>&nbsp;</p><p>Repeated use of Abstral may lead to dependence and abuse which may result in life-threatening overdose. If you have concern that you may become dependent on Abstral, it is important that you consult your doctor.</p><p>&nbsp;</p><p><u>Sleep-related breathing disorders</u></p><p>Abstral can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties in maintaining sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor.</p><p>&nbsp;</p><p><strong>Othe</strong><strong>r</strong><strong> medicine</strong><strong>s</strong><strong> and Abstral</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines (other than your regular opioid pain-relieving medicine).</p><p>&nbsp;</p><p>Some medicines may increase or decrease the effects of Abstral. Therefore if you start, change the dose of, or stop therapy with the following medication tell your doctor as they may need to adjust your dose of Abstral:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of antifungal medicines containing e.g. ketoconazole or itraconazole (used to treat fungal infections).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of antibiotic medicines called macrolides, containing e.g. erythromycin (used to treat infections).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of antiviral medicines called protease inhibitors, containing e.g. ritonavir (used to treat infections caused by viruses).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampin or rifabutin (medicines used to treat bacterial infections).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine, phenytoin or phenobarbital (medicines used to treat convulsions/fits).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Herbal medicines containing St John&rsquo;s wort (<em>Hypericum perforatum)</em>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines containing alcohol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines called monoamine-oxidase (MAO) inhibitors, which are used for severe depression and Parkinson&rsquo;s disease. Tell your doctor if you have taken this type of medicine within the last two weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of strong pain killers, called partial agonist/antagonists e.g. buprenorphine, nalbuphine and pentazocine (medicines for treatment of pain). You could experience symptoms of withdrawal syndrome (nausea, vomiting, diarrhoea, anxiety, chills, tremor, and sweating) while using these medicines.</p><p>&nbsp;</p><p>Abstral may add to the effect of medicines that make you feel sleepy (sedative medicines), including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other <strong>stro</strong><strong>n</strong><strong>g pai</strong><strong>n</strong><strong>-re</strong><strong>l</strong><strong>ieving</strong><strong> </strong><strong>medicines</strong> (opioid-type medicines e.g. for pain and cough)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some painkillers for nerve pain (gabapentin and pregabalin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; general anaesthetics (used to make you sleep during operations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle relaxants</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleeping tablets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat</p><p>o&nbsp;&nbsp; depression</p><p>o&nbsp;&nbsp; allergies</p><p>o&nbsp;&nbsp; anxiety (such as benzodiazepines e.g. diazepam) and psychosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing clonidine (used to treat high blood pressure)</p><p>&nbsp;</p><p>Use of Abstral at the same time as medicines that make you feel sleepy (sedative medicines), such as benzodiazepines, increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, use of Abstral together with sedative medicines should only be considered when other treatment options are not possible.</p><p>&nbsp;</p><p>However, if your doctor does prescribe Abstral together with sedative medicines, the dose and duration of treatment should be limited by your doctor.</p><p>&nbsp;</p><p>Please tell your doctor about all sedative medicines you are taking, and follow your doctor&rsquo;s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.</p><p>&nbsp;</p><p>The risk of certain other side effects increases if you are taking medicines such as certain antidepressants or antipsychotics. Abstral may interact with these medicines and you may experience mental status changes (e.g. agitation, hallucinations, coma), and other effects, such as body temperature above 38&deg;C, increase in heart rate, unstable blood pressure, and exaggeration of reflexes, muscular rigidity, lack of coordination and/or gastrointestinal symptoms (e.g nausea, vomiting, diarrhoea). Your doctor will tell you whether Abstral is suitable for you.</p><p>&nbsp;</p><p><strong>Abstral</strong><strong> with</strong><strong> </strong><strong>foo</strong><strong>d</strong><strong>, drin</strong><strong>k</strong><strong> an</strong><strong>d</strong><strong> alco</strong><strong>h</strong><strong>ol</strong></p><p>&nbsp;</p><p>Abstral can make some people feel drowsy. &nbsp;Do not consume alcohol without consulting your doctor as it might make you feel more drowsy than usual.</p><p>&nbsp;</p><p>Do not drink grapefruit juice while you are prescribed Abstral treatment as it may increase the side effects of Abstral.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong><strong> </strong><strong>and</strong><strong> </strong><strong>breas</strong><strong>t</strong><strong>-feeding</strong></p><p><strong>&nbsp;</strong></p><p>You must not use Abstral during pregnancy unless you have been specifically told to by your doctor.</p><p><strong><u>&nbsp;</u></strong></p><p>Fentanyl can get into breast milk and may cause side effects in the breast-fed infant. Do not use Abstral if you are breast-feeding. You should not start breast-feeding until at least 5 days after the last dose of Abstral.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine when pregnant or breast-feeding.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and</strong><strong> </strong><strong>using</strong><strong> </strong><strong>machines</strong></p><p>&nbsp;</p><p>Abstral may impair your mental and/or physical ability to perform potentially hazardous tasks such as driving or operating machinery.</p><p>&nbsp;</p><p>If you feel dizzy, sleepy or have blurred vision when you take Abstral, do not drive or use machinery.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist if you are not sure whether it is safe for you to drive while taking this medicine.</p><p>&nbsp;</p><p><strong>Abstral contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Before taking Abstral for the first time your doctor will explain how Abstral should be taken to effectively treat your breakthrough pain.&nbsp;</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you.&nbsp; Check with your doctor or pharmacist if you are not sure.&nbsp;</p><p>&nbsp;</p><p>This product should ONLY be used by you according to your doctor&rsquo;s instructions.&nbsp; It should not be used by anyone else as it could present a SERIOUS risk to their health, especially in children.</p><p>&nbsp;</p><p>Abstral is a different type of medication from other medicines you may have used to treat your breakthrough pain.<strong>&nbsp; You must always use the dose of </strong><strong>Abstral as prescribed by your doctor</strong> &ndash; this may be a different dose from that which you have used with other medicines for breakthrough pain.</p><p>&nbsp;</p><p><strong><u>Starting Treatment &ndash; Finding the most appropriate dose </u></strong></p><p>&nbsp;</p><p>For Abstral to work successfully, your doctor will need to identify the most appropriate dose for treating your breakthrough pain.&nbsp; Abstral is available in a range of strengths. You may need to try different strengths of Abstral over a number of episodes of breakthrough pain to find the most appropriate dose. &nbsp;Your doctor will help you do this and will work with you to find the best dose to use.&nbsp;</p><p>&nbsp;</p><p>If you do not get adequate pain relief from one dose your doctor may ask you to take an extra dose to treat an episode of breakthrough pain.&nbsp; Do not take a second dose <strong>unles</strong><strong>s</strong><strong> you</strong><strong>r</strong><strong> docto</strong><strong>r</strong><strong> tell</strong><strong>s</strong><strong> yo</strong><strong>u</strong><strong> to,</strong> as this may result in overdose.&nbsp;</p><p>&nbsp;</p><p>Sometimes your doctor may advise you to take a dose which consists of more than one tablet at a time. <strong>Onl</strong><strong>y</strong><strong> do thi</strong><strong>s</strong><strong> if direc</strong><strong>t</strong><strong>ed</strong><strong> </strong><strong>by</strong><strong> </strong><strong>your</strong><strong> </strong><strong>docto</strong><strong>r</strong><strong>.</strong></p><p><strong>&nbsp;</strong></p><p>Wait at least 2 hours from taking your last dose before treating your next episode of breakthrough pain with Abstral.</p><p>&nbsp;</p><p><strong><u>Continuing Treatment - Once you have found the most appropriate dose</u></strong></p><p>&nbsp;</p><p>Once you and your doctor have found a dose of Abstral that controls your breakthrough pain you should take this dose no more than four times a day. <strong>&nbsp;</strong><strong>A dose</strong><strong> </strong><strong>of </strong><strong>Abstral</strong><strong> may</strong><strong> </strong><strong>consist</strong><strong> </strong><strong>of</strong><strong> </strong><strong>more</strong><strong> </strong><strong>than</strong><strong> </strong><strong>one</strong><strong> </strong><strong>tablet.</strong></p><p><strong><u>&nbsp;</u></strong></p><p>Wait at least 2 hours from taking your last dose before treating your next episode of breakthrough pain with Abstral.</p><p>&nbsp;</p><p>If you think that the dose of Abstral that you are using is not controlling your breakthrough pain satisfactorily tell your doctor, as he may need to adjust your dose.</p><p>&nbsp;</p><p>You must not change your dose of Abstral unless directed by your doctor.</p><p>&nbsp;</p><p><strong><u>Taking the medicine</u></strong></p><p>&nbsp;</p><p>Abstral should be used sublingually. This means that the tablet should be placed under the tongue where it dissolves rapidly in order to allow fentanyl to be absorbed across the lining of the mouth.&nbsp; Once absorbed, fentanyl starts to work to relieve pain.</p><p>When you get an episode of breakthrough pain, take the dose advised by your doctor as follows:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your mouth is dry, take a sip of water to moisten it. &nbsp;Spit out or swallow the water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the tablet(s) from the blister pack immediately before use as follows:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Separate one of the blister squares from the pack by tearing along the dotted lines/perforations (keep the remaining blister squares together)</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel back the edge of the foil where the arrow is shown and gently remove the tablet.&nbsp; Do not try to push Abstral sublingual tablets through the foil top, as this will damage them.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the tablet under your tongue as far back as you can and let it dissolve completely.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abstral will dissolve rapidly under the tongue and be absorbed in order to provide pain relief.&nbsp; It is therefore important that you do not suck, chew or swallow the tablet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should not drink or eat anything until the tablet has completely dissolved under your tongue.&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Abstral than you should</strong></p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>remove any remaining tablets from your mouth</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>tell your carer or another person what has happened</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>you or your carer should immediately contact your doctor, pharmacist or local hospital and discuss what action to take</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>while waiting for the doctor, keep the person awake by talking to or shaking her/him now and then</p><p>&nbsp;</p><p>Symptoms of overdose include:</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>extreme drowsiness</p><p>&middot;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>slow, shallow breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;coma</p><p>&nbsp;</p><p>If these occur, seek emergency medical help immediately.</p><p>&nbsp;</p><p>If you think someone has taken Abstral by accident seek emergency medical help immediately.</p><p><strong>&nbsp;</strong></p><p><strong>If</strong><strong> </strong><strong>you</strong><strong> </strong><strong>stop</strong><strong> </strong><strong>taking</strong><strong> </strong><strong>Abstral</strong></p><p>You should discontinue Abstral when you no longer have any breakthrough pain. You must however continue to take your usual opioid pain-relieving medicine to treat your persistent cancer pain as advised by your doctor. You may experience withdrawal symptoms similar to the possible side effects of Abstral when discontinuing Abstral. If you experience withdrawal symptoms or if you are concerned about your pain relief you should contact your doctor. Your doctor will evaluate if you need medicine to reduce or eliminate the withdrawal symptoms.</p><p>&nbsp;</p><p>There is a risk that you may become addicted to or dependent on these tablets (a need to keep taking the medicines). If you take these for a long time you can become used to the effects and you may need to take higher doses to control your pain.</p><p>&nbsp;</p><p>You should not suddenly stop taking these tablets unless your doctor tells you to. If you want to stop taking you tablets, discuss this with your doctor first. They will tell you how to do this, usually by reducing the dose gradually so you do not experience unpleasant effects. If you suddenly stop taking these tablets you may get withdrawal symptoms such as</p><p>- agitation,</p><p>- anxiety,</p><p>- palpitations,</p><p>- shaking or</p><p>- sweating</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side-effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>If yo</strong><strong>u</strong><strong> star</strong><strong>t</strong><strong> to feel</strong><strong> </strong><strong>unusually</strong><strong> </strong><strong>or</strong><strong> </strong><strong>extremely</strong><strong> </strong><strong>sleepy</strong><strong> </strong><strong>or</strong><strong> </strong><strong>your</strong><strong> </strong><strong>breathing</strong><strong> </strong><strong>becomes</strong><strong> </strong><strong>slow</strong><strong> </strong><strong>or</strong><strong> </strong><strong>shallow,</strong><strong> </strong><strong>you</strong><strong> </strong><strong>or </strong><strong>your</strong><strong> carer</strong><strong> </strong><strong>shoul</strong><strong>d</strong><strong> immediately</strong><strong> </strong><strong>contact</strong><strong> </strong><strong>you</strong><strong>r</strong><strong> doctor</strong><strong> </strong><strong>or local hospital</strong><strong> </strong><strong>fo</strong><strong>r</strong><strong> emergenc</strong><strong>y</strong><strong> help (se</strong><strong>e</strong><strong> also </strong><strong>section </strong><strong>3 &ldquo;If</strong><strong> </strong><strong>you</strong><strong> </strong><strong>take</strong><strong> </strong><strong>more</strong><strong> </strong><strong>Abstral</strong><strong> </strong><strong>th</strong><strong>a</strong><strong>n you</strong><strong> </strong><strong>should&rdquo;</strong><strong>)</strong><strong>.</strong></p><p>&nbsp;</p><p>Very common side effects (may affect more than 1 in 10 people) include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people) include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, headache, excessive sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathlessness/shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation inside the mouth, vomiting, constipation, dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating, weary/tired/lack of energy</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people) include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction, trembling/shaking, disturbed or blurred vision, fast or slow heart beat, low blood pressure, memory loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression, suspicious thoughts/ feeling afraid for no reason, feeling confused, feeling disorientated, feeling anxious/unhappy/restless, feeling unusually happy/healthy, mood swings</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling full all the time, stomach-ache, indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth ulcers, problems with tongue, pain in mouth or throat, tightness in throat, lip or gum ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite, loss of or change in sense of smell/taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping or disturbed sleep, disturbance in attention/easily distracted, lack of energy/weakness/loss of strength</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormality in skin, rash, itchiness, night sweats, decreased sensitivity to touch, bruising easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain or stiffness, stiffness in muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drug withdrawal symptoms<em>, (ma</em><em>y</em><em> manife</em><em>s</em><em>t by</em><em> </em><em>the</em><em> </em><em>occurrence</em><em> </em><em>of</em><em> </em><em>the</em><em> </em><em>following</em><em> </em><em>side</em><em> </em><em>effects:</em><em> </em><em>nausea, </em><em>v</em><em>omiting,</em><em> </em><em>diarrhoea,</em><em> </em><em>anxiet</em><em>y</em><em>, chills,</em><em> </em><em>tremo</em><em>r</em><em>, an</em><em>d</em><em> sweatin</em><em>g</em><em>),</em> accidental overdose, in males an inability to get and/or keep an erection, feeling generally unwell</p><p>&nbsp;</p><p>Side effects of frequency not known: (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen tongue, severe breathing problems, fall, flushing, feeling very warm, diarrhoea, convulsion (fits), swelling of arms or legs, seeing or hearing things that are not really there (hallucinations), fever, drug dependence (addiction), drug abuse, reduced level or loss of consciousness, itchy rash and delirium (symptoms may include a combination of agitation, restlessness, disorientation, confusion, fear, seeing or hearing things that are not really there, sleep disturbance, nightmares).</p><p>&nbsp;</p><p>Prolonged treatment with fentanyl during pregnancy may cause withdrawal symptoms in the newborn which can be life-threatening (see section 2).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Reporting of</strong><strong> </strong><strong>side</strong><strong> </strong><strong>effects</strong><strong> </strong></p><p>If you get any side effects, talk to your &nbsp;doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The pai</strong><strong>n</strong><strong>-relieving</strong><strong> </strong><strong>medicine</strong><strong> </strong><strong>in</strong><strong> </strong><strong>Abstral</strong><strong> </strong><strong>is very</strong><strong> </strong><strong>strong</strong><strong> </strong><strong>and coul</strong><strong>d</strong><strong> be lif</strong><strong>e</strong><strong>-threatening</strong><strong> </strong><strong>if</strong><strong> </strong><strong>taken </strong><strong>a</strong><strong>ccidentall</strong><strong>y</strong><strong> by a child</strong><strong>.</strong><strong> Abstral</strong><strong> </strong><strong>must</strong><strong> </strong><strong>be</strong><strong> </strong><strong>kept</strong><strong> </strong><strong>out</strong><strong> </strong><strong>of</strong><strong> </strong><strong>the</strong><strong> </strong><strong>sight and reach</strong><strong> </strong><strong>of</strong><strong> </strong><strong>children.</strong></p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister after EXP.&nbsp; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 25&deg;C.</p><p>&nbsp;</p><p>Store in the original blister in order to protect from moisture.</p><p>&nbsp;</p><p>It is recommended to keep Abstral in a locked storage space.</p><p>&nbsp;</p><p>Any unused product should be taken, if possible, to your pharmacist to be disposed of safely.&nbsp; Do not throw away any medicines via wastewater or household waste.&nbsp; These measures will help protect the environment.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is fentanyl. One sublingual tablet contains:</p><p>&nbsp;</p><p>100&nbsp;micrograms fentanyl (as citrate)</p><p>200&nbsp;micrograms fentanyl (as citrate)</p><p>&nbsp;</p><p>The other ingredients are mannitol (E421), silicified microcrystalline cellulose, croscarmellose sodium and magnesium stearate.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                		Abstral is a small white sublingual tablet to be inserted under the tongue. It comes in a range of different strengths and shapes. Your doctor will prescribe the strength (shape) and number of tablets suitable for you.
	
The 100 microgram tablet is a white round tablet
The 200 microgram tablet is a white oval-shaped tablet

Abstral tablets are contained in blisters, available in cartons of 10 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing</strong><strong> Authorisation Holder:</strong><strong> </strong></p><p>Kyowa Kirin Ltd</p><p>Galabank Business Park</p><p>Galashiels</p><p>TD1 1QH</p><p>UK</p><p>&nbsp;</p><p><strong>Manufacturer</strong><strong>&amp; Batch Releaser</strong><strong>:</strong></p><p>&nbsp;</p><p>RECIPHARM LEGAN&Eacute;S S.L.U.,</p><p>Calle Severo Ochoa 13 Legan&eacute;s, 28914 (Madrid),</p><p>Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sep/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">دواء أبسترال هو علاج للبالغين الذين <strong>يجب أن يكونوا مواظبين بالفعل على تناوُل مُسَكِّن قوي للآلام (الأفيونات)</strong> لعلاج ألم السرطان المستمر، لكن يحتاجون إلى علاج للآلام المفاجئة. إذا لم تكن متأكدًا، فيُرجى التحدُّث إلى طبيبك.</p><p dir="RTL">الألم المفاجئ هو ألم يحدث فجأةً، على الرغم من تناوُلك أو استخدامك للمُسَكِّن الأفيوني الذي تتناوله عادة لتسكين الألم.</p><p dir="RTL">المادة الفعَّالة في دواء أبسترال أقراص للوضع تحت اللسان هي فينتانيل. ينتمي فينتانيل إلى فئة من مُسَكِّنات الآلام القوية تُدعى الأفيونات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول دواء أبسترال في الحالات الآتية:</strong></p><p dir="RTL">&bull; إذا كنت تُعاني من حساسية تجاه فينتانيل أو أي من المكونات الأخرى بهذا الدَّواء (المُدرَجة في قسم 6).</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل شديدة في التَّنفس.</p><p dir="RTL">&bull; إذا لم تكن مواظبًا على استخدام دواء أفيوني موصوف لك يوميًّا وفق جدول منتظم لأسبوع على الأقل للسيطرة على الألم المستمر لديك (على سبيل المثال: كودين، فينتانيل، هيدرومورفون، مورفين، أوكسيكودون، بيثيدين). إذا لم تكن تستخدم هذه الأدوية، <strong>فيجب عليك ألا</strong> تتناول دواء أبسترال؛ لأنه قد يرفع خطر تباطؤ التَّنفس و/أو تضحله إلى حد خطير، أو حتى توقفه.</p><p dir="RTL">&bull; إذا كنت تُعاني من ألم قصير المدى بخلاف نوبات الألم المفاجئ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعالَج حاليًّا بأدوية تحتوي على أوكسيبات الصوديوم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ت</strong><strong>حذيرات واحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى الطبيب أو الصيدلي الخاص بك قبل تناوُل دواء أبسترال إذا كنت تُعاني أو قد عانيت مؤخرًا مما يلي؛ إذ سيحتاج طبيبك إلى أن يضع هذا في الاعتبار عند وصف جرعتك من الدَّواء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة بالرأس؛ إذ قد يخفي دواء أبسترال مدى الإصابة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالتَّنفس أو إذا عانيت من الوهن العضلي الوبيل (حالة تتسم بضعف العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشاكل بالقلب، لا سيما بطء معدل ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض بالكبد أو الكلى؛ إذ قد يستدعي هذا من طبيبك بذل عناية أكبر في تعديل جرعتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم بالمخ، و/أو ارتفاع الضغط داخل الجمجمة (ارتفاع الضغط في المخ، مما يُسبب الصُّداع الشديد والغثيان/ القيء وعدم وضوح الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جروح بالفم أو التهاب الأغشية المخاطية (تورُّم واحمرار داخل الفم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مضادات الاكتئاب أو مضادات الذّهان، فيُرجى الرجوع إلى قسم: &quot;الأدوية الأخرى ودواء أبسترال&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت من قبل بقصورٍ كظري أو نقصٍ بالهرمونات الجنسية (نقص الأندروجين) مع استخدام المواد الأفيونية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند تناوُل دواء أبسترال، قم بإبلاغ طبيبك أو طبيب الأسنان الخاص بك بأنك تتناول هذا الدَّواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ستخضع لأي جراحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت ألمًا أو زيادة الحساسية للألم (فرط التَّألم) الذي لا يستجيب لجرعة أعلى من الدَّواء الخاص بك على النحو الموصوف من قبل طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من مجموعة من الأعراض التَّالية: غثيان، قيء، فقدان الشهية، إرهاق، ضعف، دوخة وانخفاض ضغط الدَّم. معًا، قد تكون هذه الأعراض علامة على وجود حالة مهددة للحياة تُعرف باسم قصور الكظر، وهي حالة لا تقوم بها الغدد الكظرية بإفراز ما يكفي من الهرمونات.</p><p dir="RTL">قد يحتاج طبيبك إلى فحصك عن كثب في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أدمنت أو أدمن أحد أفراد أسرتك شرب الكحوليات أو تناوُل الأدوية الوصفية أو العقاقير غير القانونية أو اعتمدت عليها أو اعتمد عليها أحد أفراد أسرتك سابقًا (&quot;الإدمان&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; إذا كنت مدخنًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; إذا عانيت سابقًا من مشاكل في حالتك المزاجية (اكتئاب أو قلق أو اضطراب في الشخصية) أو عالجك طبيب نفسي سابقًا من أمراض نفسية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي تكرار استخدام دواء أبسترال إلى إدمانه والاعتماد عليه ما قد يتسبب في تناوُل جرعة زائدة مهددة للحياة. من المهم أن تستشير طبيبك إذا كنت قلقًا من أن تصبح معتمدًا على دواء أبسترال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>اضطرابات التَّنَفُّس المرتبطة بالنوم</u></p><p dir="RTL">قد يسبب دواء أبسترال اضطرابات في التَّنَفُّس مرتبطة بالنوم مثل: انقطاع التَّنَفُّس (توقف التَّنَفُّس أثناء النوم) ونقص تأكسج الدم المرتبط بالنوم (انخفاض مستوى الأكسجين بالدم). قد تشمل الأعراض انقطاعًا في التَّنَفُّس أثناء النوم أو الاستيقاظ ليلًا بسبب ضيق النفس أو صعوبات بالاستغراق في النوم أو نعاسًا زائدًا خلال النهار. اتصل بطبيبك إذا لاحظت هذه الأعراض أو لاحظها غيرك. قد يأخذ طبيبك بعين الاعتبار خفض الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الأدوية الأخرى ودواء أبسترال</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تتناول، أو قد تناولت مؤخرًا، أو قد تتناول أيَّة أدوية أخرى (بخلاف المُسَكِّن الأفيوني).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تُؤدي بعض الأدوية إلى زيادة أو نقص تأثيرات دواء أبسترال. لذلك، أخبر طبيبك إذا بدأت العلاج بالأدوية التَّالية،</p><p dir="RTL">أو قمت بتغيير جرعتها أو قمت بإيقافها؛ حيث قد يحتاج إلى تعديل الجرعة الخاصة بك من دواء أبسترال:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع مضادات الفطريات التي تحتوي -على سبيل المثال-على كيتوكونازل أو إتراكونازول (يُستخدمان لعلاج العدوى الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع المضادات الحيوية التي تُدعى الماكرولايدات التي تحتوي -على سبيل المثال-على إريثروميسين (يُستَخدَم لعلاج العدوى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع مضادات الفيروسات التي تُدعى مثبطات البروتياز التي تحتوي -على سبيل المثال-على ريتونافير (يُستَخدَم لعلاج العدوى الناتجة عن الفيروسات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبين أو ريفابوتين (أدوية تُستخدم لعلاج العدوى البكتيرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كَرْبامازِيبين، فينيتوين أو فينوباربيتال (أدوية تُستخدم لعلاج التشنجات/ النوبات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية العشبية التي تحتوي على نبتة سانت جونز <em>(</em><em>هايبريكوم برفوراتام</em><em>).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على الكحول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُدعى مثبطات الأوكسيديز أحادي الأمين، وتُستَخدَم لعلاج الاكتئاب الشديد ومرض الشلل الرعَّاش (مرض باركنسون). أخبر طبيبك إذا كنت قد تناولت هذا النوع من الأدوية خلال الأسبوعين الماضيين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع مسكنات الألم القوية، والتي تُدعى المحفزات/ المضادات الجزئية، على سبيل المثال، بوبرينورفين ونالبيوفين وبنتازوسين (أدوية لعلاج الألم).&nbsp; قد تواجه أعراض متلازمة الانسحاب (غثيان وقيء وإسهال وقلق وقشعريرة وارتعاش وتعرُّق) أثناء استخدام هذه الأدوية.</p><p dir="RTL">قد يدخل دواء أبسترال ضمن الأدوية التي تُشعِرُك بالنُّعاس (الأدوية المهدئة)، بما في ذلك:</p><p dir="RTL">&bull; <strong>المسكنات الأخرى القوية</strong> (الأدوية الأفيونية لعلاج الألم والسُّعال -على سبيل المثال-)</p><p dir="RTL">&bull; بعض مسكنات الآلام العصبية (جابابينتين وبريجابالين)</p><p dir="RTL">&bull; أدوية التَّخدير العام (تُستَخدَم للتنويم أثناء العمليات).</p><p dir="RTL">&bull; مُرخيات العضلات.</p><p dir="RTL">&bull; أقراص النَّوم.</p><p dir="RTL">&bull; الأدوية التي تُستَخدَم لعلاج</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق (مثل: البِنزوديازيبينات على سبيل المثال: ديازيبام) &nbsp;والذهان</p><p dir="RTL">&bull; الأدوية التي تحتوي على الكلونيدين (يُستَخدَم لعلاج ارتفاع ضغط الدَّم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يزيد استخدام دواء أبسترال بشكل متزامن مع الأدوية التي تشعرك بالنعاس (الأدوية المهدئة)، مثل: البِنزوديازيبينات، من خطر الشعور بالنعاس أو مواجهة صعوبات في التَّنَفُّس (كبت الجهاز التنفسي) أو الدخول في غيبوبة وقد يكون الأمر مهددًا للحياة. لذلك، ينبغي ألا يُؤخذ استخدام دواء أبسترال بمصاحبة الأدوية المهدئة بعين الاعتبار إلا عندما تكون الخيارات العلاجية الأخرى غير ممكنة.</p><p dir="RTL">مع ذلك، في حال وَصفَ طبيبك دواء أبسترال بمصاحبة الأدوية المهدئة، ينبغي على طبيبك حينها أن يحدد جرعة العلاج ومدته.</p><p dir="RTL">أخبر طبيبك بكافة الأدوية المهدئة التي تتناولها واتَّبِع تعليمات طبيبك اتباعًا دقيقًا فيما يخص الجرعة.<strong> </strong>قد يكون من المفيد إعلام الأصدقاء أو الأقارب بالعلامات والأعراض المذكورة أعلاه كي يكونوا على دراية بها. أتصل بطبيبك عند التعرض لمثل هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرتفع خطر بعض الأثار الجانبية الأخرى إذا كنت تتناول أدوية مثل بعض مضادات الاكتئاب أو مضادات الذهان. قد يتداخل دواء أبسترال مع هذه الأدوية، وقد تتعرض لتغيرات في الحالة العقلية (على سبيل المثال: الهياج، الهلاوس، الغيبوبة) وتأثيرات أخرى، مثل: ارتفاع درجة حرارة الجسم عن 38 درجة مئوية، وارتفاع مُعدَّل ضربات القلب، وعدم استقرار ضغط الدَّم، والمبالغة في ردود الفعل، والصمل العضلي، والافتقار إلى التنسيق، و/أو أعراض بالجهاز الهضمي (على سبيل المثال: غثيان، قيء، إسهال). سيخبرك طبيبك إذا كان دواء أبسترال يناسبك أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>تناوُل دواء أبسترال مع الأغذية والمشروبات والكحوليات</strong></p><p dir="RTL">قد يُسبب دواء أبسترال للبعض الشُّعور بالنُّعاس. لا تتناول الكحوليات بدون استشارة طبيبك؛ إذ قد يجعلك هذا تشعر بنعاس أكثر من المعتاد.</p><p dir="RTL">لا تشرب عصير الجريب فروت أثناء وصف العلاج بدواء أبسترال لك، فقد يُزيد الآثار الجانبية لدواء أبسترال.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب عليكِ عدم استخدام دواء أبسترال أثناء الحمل إلا إذا أخبركِ طبيبكِ تحديدًا بذلك.</p><p dir="RTL">قد تنتقل مادة فينتانيل إلى لبن الأم، وقد تسبب آثارًا جانبية للرُّضع. لا تستخدمي دواء أبسترال إذا كنتِ مرضعًا. يجب عليكِ عدم البدء في الإرضاع حتى مرور 5 أيام على الأقل على آخر جرعة من دواء أبسترال.</p><p dir="RTL">استشيري الطبيب أو الصيدلي الخاص بكِ قبل تناوُل أي دواء أثناء حملكِ أو ممارستكِ الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;<strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يُضعِف دواء أبسترال قدرتك الذهنية و/أو البدنية على أداء المهام التي قد تتسم بالخطورة مثل القيادة أو تشغيل الآلات.</p><p dir="RTL">إذا شعرت بدوخة، أو نُعاس، أو كنت تعاني من عدم وضوح الرؤية عند تناوُل دواء أبسترال، فتجنَّب القيادة أو استخدام الآلات.</p><p>&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا مما إذا كانت ممارستك القيادة خلال فترة تناولك لهذا الدَّواء تصرفًا آمنًا.</p><p dir="RTL"><strong>أبسترال</strong><strong> يحتوى على</strong> <strong>صوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملليمول من الصوديوم (23 ميلليجرام) لكل قرص ، أي &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيوضح لك طبيبك الكيفية التي يجب بها تناول دواء أبسترال قبل تناوله للمرة الأولى لعلاج الألم المفاجئ لديك بفعالية.</p><p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة الطبيب أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التَّناول.</p><p dir="RTL">يجب أن تستخدم هذا المُنتَج فقط وفقًا لتعليمات الطبيب. يجب ألا يَستخدم هذا الدَّواء أيُّ شخص آخر؛ إذ إنه قد يُشكل خطرًا كبيرًا على صحته، لا سيما في الأطفال.</p><p dir="RTL">يختلف دواء أبسترال عن الأدوية الأخرى التي يمكن أن تكون قد استخدمتها لعلاج الألم المفاجئ لديك. <strong>يجب عليك دائمًا استخدام جرعة دواء أبسترال كما وصفها لك طبيبك</strong>- قد تختلف هذه الجرعة عن الجرعة التي استخدمتها عند تناوُل أدوية أخرى لعلاج الألم المفاجئ.</p><p dir="RTL"><strong><u>بدء العلاج- تحديد الجرعة الأنسب</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحتاج طبيبك لتحديد الجرعة الأنسب لك لعلاج الألم المفاجئ، كي يعمل دواء أبسترال بنجاح. يتوفر دواء أبسترال بتركيزات مختلفة. قد تحتاج لتجربة تركيزات مختلفة من دواء أبسترال على مدى عدد من نوبات الألم المفاجئ لاكتشاف الجرعة الأنسب لك. سيُساعدك طبيبك على القيام بذلك، وسيعمل معك لتحديد الجرعة الأمثل لك.</p><p dir="RTL">إذا لم تكن جرعة واحدة كافية لتسكين الألم، فقد يطلب منك طبيبك تناوُل جرعة إضافية لعلاج نوبات الألم المفاجئ. لا تتناول جرعة ثانية<strong> ما لم يخبرك طبيبك بذلك؛</strong> إذ قد يُؤدي هذا إلى تناوُلك جرعة زائدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد ينصحك طبيبك في بعض الأحيان بتناوُل جرعة تتكون من أكثر من قرص من الدواء بالمرة الواحدة. <strong>قم بذلك فقط بتوجيه من الطبيب.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">انتظر ساعتين على الأقل بعد تناوُل الجرعة الأخيرة من دواء أبسترال قبل علاج نوبة الألم المفاجئة التَّالية بدواء أبسترال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>مواصلة العلاج- فور توصلك للجرعة الأنسب لك</u></strong><strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك عدم تناوُل هذه الجرعة لأكثر من أربع مرات يوميًّا فور توصلك مع طبيبك إلى جرعة دواء أبسترال التي تتحكم في الألم المفاجئ لديك. <strong>قد تتألف جرعة دواء أبسترال من أكثر من قرص واحد.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">انتظر ساعتين على الأقل بعد تناوُل الجرعة الأخيرة من دواء أبسترال قبل علاج نوبة الألم المفاجئة التَّالية بدواء أبسترال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت ترى أن جرعة دواء أبسترال التي تستخدمها لا تسيطر بشكل كافٍ على الألم المفاجئ لديك، فأخبر طبيبك؛ إذ قد يحتاج لتعديل جرعتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك عدم تغيير جرعتك من دواء أبسترال ما لم يوجهك طبيبك بذلك.</p><p dir="RTL"><strong><u>تناوُل الدَّواء</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يُستَخدَم دواء أبسترال عن طريق الوضع تحت اللسان. هذا يعني أن القرص يجب أن يوضع تحت اللسان حيث يذوب سريعًا للسماح بامتصاص فينتانيل عبر بطانة الفم. يبدأ فينتانيل العمل فور امتصاصه لتسكين الألم.</p><p dir="RTL">عند إصابتك بنوبة ألم مفاجئ، تناول الجرعة التي ينصحك طبيبك بها كما يلي:</p><p dir="RTL">&bull; إذا كان فمك جافًا، تناول رشفة من الماء لترطيبه. ابصق أو ابتلع الماء.</p><p dir="RTL">&bull; أخرج القرص (الأقراص) من عبوة الشرائط قبل الاستخدام مباشرة كالتَّالي.</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بفصل أحد المربعات الموجودة على شريط العبوة عن سائر المربعات بتمزيق الشريط على طول الخطوط المنقوطة/ المثقبة (اترك سائر مربعات الشريط معًا).</p><p dir="RTL">&Oslash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتقشير حافة الرقاقة حيث يظهر السهم، وأخرج القرص برفق. لا تحاول دفع أقراص دواء أبسترال للوضع تحت اللسان من أعلى الرقاقة؛ إذ إن هذا سيتلفها.</p><p dir="RTL">&bull; ضع القرص بأبعد موضع ممكن تحت لسانك، واتركه يذوب تمامًا.</p><p dir="RTL">&bull; سيذوب دواء أبسترال سريعًا تحت اللسان، ويتم امتصاصه لتسكين الألم. لذلك من المهم ألا تمتص القرص، أو تمضغه، أو تبتلعه.</p><p dir="RTL">&bull; يجب عليك عدم شرب أو تناول أي شيء حتى يذوب القرص تمامًا تحت لسانك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية من دواء أبسترال أكثر مما يجب</strong></p><p dir="RTL">&bull; قم بإزالة أي أقراص متبقية من تحت لسانك.</p><p dir="RTL">&bull; أخبر مقدم الرعاية الخاص بك أو شخص آخر بما حدث.</p><p dir="RTL">&bull; يجب عليك أو على مقدم الرعاية الخاص بك إبلاغ الطبيب أو الصيدلي الخاص بك أو المستشفى المحلي على الفور ومناقشة الإجراء الذي سيتم اتخاذه.</p><p dir="RTL">&bull; أثناء انتظار الطبيب، أبقِ المريض/ المريضة يقظًا/ يقظة بالتَّحدُّث إليه/ إليها أو هزه/ هزها من حين لآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أعراض الجرعة الزائدة تشمل:</p><p dir="RTL">&bull; النُّعاس الشديد.</p><p dir="RTL">&bull; التَّنفس البطيء الضحل.</p><p dir="RTL">&bull; الغيبوبة.</p><p dir="RTL">إذا حدثت لك هذه الأعراض، اطلب المساعدة الطبية الطارئة فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أن أحد الأشخاص تناول دواء أبسترال بطريق الخطأ، فاطلب المساعدة الطبية الطارئة فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناوُل دواء أبسترال</strong></p><p dir="RTL">يجب أن تتوقف عن تناوُل دواء أبسترال عندما يزول لديك أي ألم مفاجئ. مع ذلك، يجب عليك مواصلة تناوُل المسكن الأفيوني الذي تتناوله بشكل معتاد لتسكين ألم السرطان المستمر لديك كما نصحك طبيبك. قد تواجه أعراض انسحاب مماثلة للآثار الجانبية المُحتَمَلة لدواء أبسترال عند إيقافه. إذا واجهت أعراض الانسحاب أو إذا كنت قلقًا بشأن كيفية تسكين الألم لديك فعليك الاتصال بطبيبك. سيقيِّم طبيبك ما إذا كنت تحتاج إلى تناوُل الدواء لخفض أو إزالة أعراض الانسحاب.</p><p dir="RTL">توجد احتمالية للتعرُّض لخطر أن تصير مدمنًا لهذه الأقراص أو معتمدًا عليها (الحاجة إلى الاستمرار في تناوُل الأدوية). إذا تناولت الأقراص لفترة طويلة فقد تعتاد على تأثيراتها وقد تحتاج إلى تناوُل جرعات أكبر للتحكم في الألم الذي تعاني منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تتوقف فجأةً عن تناول هذه الأقراص إلا إذا أخبرك طبيبك بذلك. إذا كنت ترغب في التوقف عن تناوُل الأقراص، فناقش هذا الأمر مع طبيبك أولًا، وهو بدوره سيخبرك بكيفية فعل ذلك، ويكون ذلك عادةً عن طريق تقليل الجرعة تدريجيًّا حتى لا تتعرَّض لآثار جانبية مزعجة. إذا توقفت فجأةً عن تناوُل هذه الأقراص فقد تظهر عليك أعراض انسحاب مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هياج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو قلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو خفقان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو ارتعاش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو تعرُّق</p><p dir="RTL">إذا كان لديك أية أسئلة أخرى حول استخدام هذا الدواء، فتحدث إلى الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>إذا بدأت تشعر بنعاس شديد، أو بشكل غير عادي، أو إذا تباطأ تنفسك، أو أصبح ضحلًا، فيجب عليك أو على مقدم الرعاية الخاص بك الاتصال بطبيبك أو المستشفى المحلي في الحال لطلب مساعدة طارئة (انظر أيضًا قسم</strong><strong> </strong><strong>3 &quot;إذا تناولت كمية أكثر مما يجب من دواء أبسترال&quot;).</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية شائعة جدًّا (قد تُؤثر في أكثر من 1 من كل 10&nbsp;أشخاص) وتشمل:</p><p dir="RTL">&bull; غثيان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">آثار جانبية شائعة (قد تُؤثر في ما يصل إلى 1 من كل 10&nbsp;أشخاص) وتشمل:</p><p dir="RTL">&bull; دوخة، صداع، نعاس مفرط.</p><p dir="RTL">&bull; عسر التَّنفس/ ضيق التَّنفس.</p><p dir="RTL">&bull; التهاب داخل الفم، قيئ، إمساك، جفاف الفم.</p><p dir="RTL">&bull; تعرُّق، تعب/ إرهاق/ نقص الطاقة.</p><p dir="RTL">آثار جانبية غير شائعة (قد تُؤثر في ما يصل إلى 1 من كل 100 شخص) وتشمل:</p><p dir="RTL">&bull; تفاعلات حساسية، ارتجاف/ ارتعاش، عدم وضوح الرؤية أو اضطرابها، تسارع أو تباطؤ ضربات القلب، انخفاض ضغط الدَّم، فقدان الذاكرة.</p><p dir="RTL">&bull; اكتئاب، شكوك/ شعور بالخوف بلا سبب، شعور بالارتباك، شعور بالتَّوهان، شعور بالقلق/ الحزن/ التَّململ، شعور بالسعادة/ الصحة غير العادية، تقلبات مزاجية.</p><p dir="RTL">&bull; شعور بالشبع طوال الوقت، ألم بالمعدة، عسر الهضم.</p><p dir="RTL">&bull; قرح بالفم، مشاكل باللسان، ألم بالفم أو الحلق، ضيق بالحلق، قرح بالشفاه أو اللثة.</p><p dir="RTL">&bull; فقدان الشهية، فقدان أو تغير حاسة الشم/ التَّذوق.</p><p dir="RTL">&bull; صعوبة في النوم أو اضطراب النوم، تشتت الانتباه/ سهولة تشتت الانتباه.</p><p dir="RTL">نقص الطاقة/ ضعف/ فقدان القوة.</p><p dir="RTL">&bull; اضطراب بالجلد، طفح جلديّ، حكة، التعرُّق ليلًا، انخفاض حاسة اللمس، الإصابة بكدمات بسهولة.</p><p dir="RTL">&bull; ألم أو تصلب بالمفاصل، تصلب بالعضلات.</p><p dir="RTL">&bull; &nbsp;أعراض سحب الدواء (<em>قد</em><em> </em><em>تظهر</em><em> </em><em>بحدوث</em><em> </em><em>الآثار</em><em> </em><em>الجانبية</em><em> </em><em>التالية</em><em>: </em><em>غثيان</em><em> </em><em>وقيء</em><em> </em><em>وإسهال</em><em> </em><em>وقلق</em><em> </em><em>وقشعريرة</em><em> </em><em>وارتعاش</em><em> </em><em>وتعرُّق</em>)، يؤدي تناوُل جرعة زائدة بطريق الخطأ في الذكور إلى عدم القدرة على الحصول على الانتصاب و/أو الاحتفاظ به، الشعور العام بالإعياء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;آثار جانبية بمعدل تكرار غير معروف: (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&bull; تورُّم اللسان، مشاكل شديدة بالتَّنفس، سقوط، احمرار الجلد، شعور بدفء شديد، إسهال، تشنجات (نوبات تشنج)، تورُّم الذراعين أو الساقين، رؤية أشياء أو سماع أصوات غير موجودة (هلاوس)، حمى، الاعتماد على الدَّواء (الإدمان)، إساءة استخدام الدواء، انخفاض أو فقدان الوعي، طفح جلدي مصحوب بحكة، وهذيان (قد تشمل الأعراض: هياج، تململ، ارتباك، توهان، خوف، رؤية أو سماع أشياء&nbsp; غير موجودة بالفعل، اضطرابات بالنوم، كوابيس).</p><p dir="RTL">قد يُسبب العلاج طويل الأمد بفينتانيل أثناء الحمل حدوث أعراض انسحابٍ للطفل حديث الولادة، مما قد يكون مهددًا للحياة (انظر قسم: 2)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية </strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى الطبيب أو الصيدلي الخاص بك. ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مسكن الألم في دواء أبسترال يتسم بالقوة الشديدة، وقد يهدد الحياة إذا تناوله طفل بطريق الخطأ.</strong> <strong>يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد انتهاء تاريخ الصلاحية المُدوَّن على العبوة والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تخزن الدواء في درجة حرارة أعلى من 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفَظ داخل الشريط الأصلي للحماية من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُوصى بالاحتفاظ بدواء أبسترال في منطقة تخزين مُغلَقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أخذ أي مُنتَج لم يتم استخدامه إلى الصيدلي الخاص بك إن أمكن؛ ليتم التَّخلص منه على نحو آمن. لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. ستُساعد تلك الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعَّالة هي فينتانيل. يحتوي كل قرص يُوضَع تحت اللسان على:</p><p dir="RTL">100 ميكروجرام فينتانيل (في هيئة سيترات)،</p><p dir="RTL">200 ميكروجرام فينتانيل (في هيئة سيترات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي مانيتول (E421)، سليلوز دقيق التَّبلور مُنسَلِّك، كروسكارميلوز الصوديوم، وستيرات الماغنسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دواء أبسترال هو أقراص بيضاء صغيرة للوضع تحت اللسان، يتم إدخالها تحت اللسان. يتوفر الدواء بتركيزات وأشكال مختلفة. سيقوم طبيبك بوصف تركيز (شكل) وعدد الأقراص المناسب لك.</p><p dir="RTL">أقراص دواء أبسترال 100 ميكروجرام هي أقراص بيضاء دائرية الشكل.</p><p dir="RTL">أقراص دواء أبسترال 200 ميكروجرام هي أقراص بيضاء بيضاوية الشكل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">توجد أقراص دواء أبسترال في شرائط تتوفر بعبوات كرتونية تحتوي على 10 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">حامل رخصة التَّسويق:</p><p>&nbsp;Kyowa Kirin Ltd,</p><p dir="RTL">Galabank Business Park</p><p dir="RTL">Galashiels</p><p dir="RTL">TD1 1QH</p><p dir="RTL">UK</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنّعة</strong><strong>:</strong></p><p>RECIPHARM LEGAN&Eacute;S S.L.U., Calle Severo Ochoa 13 Legan&eacute;s, 28914 (Madrid),Spain</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abstral 100 microgram sublingual tablets Abstral 200 microgram sublingual tablets Abstral 300 microgram sublingual tablets Abstral 400 microgram sublingual tablets Abstral 600 microgram sublingual tablets Abstral 800 microgram sublingual tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each sublingual tablet contains:
100 micrograms fentanyl (as citrate) 200 micrograms fentanyl (as citrate) 300 micrograms fentanyl (as citrate) 400 micrograms fentanyl (as citrate) 600 micrograms fentanyl (as citrate) 800 micrograms fentanyl (as citrate)

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sublingual tablet

100 microgram sublingual tablet is a white round tablet
200 microgram sublingual tablet is a white oval-shaped tablet 300 microgram sublingual tablet is a white triangle-shaped tablet
400 microgram sublingual tablet is a white diamond-shaped tablet 600 microgram sublingual tablet is a white “D”-shaped tablet
800 microgram sublingual tablet is a white capsule-shaped tablet


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abstral should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain. Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.</p><p>&nbsp;</p><p><u>Method of administration:</u></p><p>Abstral sublingual tablets should be administered directly under the tongue at the deepest part. Abstral sublingual tablets should not be swallowed, but allowed to completely dissolve in the sublingual cavity without chewing or sucking. Patients should be advised not to eat or drink anything until the sublingual tablet is completely dissolved.</p><p>&nbsp;</p><p>In patients who have a dry mouth water may be used to moisten the buccal mucosa before taking Abstral.</p><p><u>Dose titration:</u></p><p>The object of dose titration is to identify an optimal maintenance dose for ongoing treatment of breakthrough pain episodes. This optimal dose should provide adequate analgesia with an acceptable level of adverse reactions.</p><p>The optimal dose of Abstral will be determined by upward titration, on an individual patient basis. Several doses are available for use during the dose titration phase. The initial dose of Abstral used should be 100 micrograms, titrating upwards as necessary through the range of available dosage strengths.</p><p>&nbsp;</p><p>Patients should be carefully monitored until an optimal dose is reached.</p><p>&nbsp;</p><p>Switching from other fentanyl containing products to Abstral must not occur at a 1:1 ratio because of different absorption profiles. If patients are switched from another fentanyl containing product, a new dose titration with Abstral is required.</p><p>&nbsp;</p><p>The following dose regimen is recommended for titration, although in all cases the physician should take into account the clinical need of the patient, age and concomitant illness.</p><p>All patients must start therapy with a single 100 microgram sublingual tablet. If adequate analgesia is not obtained within 15-30 minutes of administration of a single sublingual tablet, a supplemental (second) 100 microgram sublingual tablet may be administered. If adequate analgesia is not obtained within 15-30 minutes of the first dose an increase in dose to the next highest tablet strength should be considered for the next episode of breakthrough pain (Refer to figure below).</p><p>Dose escalation should continue in a stepwise manner until adequate analgesia with tolerable adverse reactions is achieved. The dose strength for the supplemental (second) sublingual tablet should be increased from 100 to 200 micrograms at doses of 400 micrograms and higher. This is illustrated in the schedule below. No more than two (2) doses should be administered for a single episode of breakthrough pain during this titration phase.</p><p>&nbsp;</p><p><img alt="" width="817" height="567" src="data:image/png;base64,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" /></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Strength (micrograms) of first sublingual tablet per episode of breakthrough pain</p></td><td style="vertical-align:top"><p>Strength (micrograms) of supplemental (second) sublingual tablet to be taken 15-30 minutes after first tablet, if required</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>200</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>400</p></td><td style="vertical-align:top"><p>200</p></td></tr><tr><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>200</p></td></tr><tr><td style="vertical-align:top"><p>800</p></td><td style="vertical-align:top"><p>-</p></td></tr></tbody></table><p>&nbsp;</p><p>If adequate analgesia is achieved at the higher dose, but undesirable effects are considered unacceptable, an intermediate dose (using the 100 microgram sublingual tablet where appropriate) may be administered.</p><p>&nbsp;</p><p>During titration, patients can be instructed to use multiples of 100 microgram tablets and/or 200 microgram tablets for any single dose. No more than four (4) tablets should be used at any one time.</p><p>The efficacy and safety of doses higher than 800 micrograms have not been evaluated in clinical studies in patients.</p><p>In order to minimise the risk of opioid&ndash;related adverse reactions and to identify the appropriate dose, it is imperative that patients be monitored closely by health professionals during the titration process.</p><p>During titration patients should wait at least 2 hours before treating another episode of breakthrough pain with Abstral.</p><p>&nbsp;</p><p><u>Maintenance therapy:</u></p><p>Once an appropriate dose has been established, which may be more than one tablet, patients should be maintained on this dose and should limit consumption to a maximum of four Abstral doses per day.</p><p>During the maintenance period patients should wait at least 2 hours before treating another episode of breakthrough pain with Abstral.</p><p>&nbsp;</p><p><u>Dose re-adjustment:</u></p><p>If the response (analgesia or adverse reactions) to the titrated Abstral dose markedly changes, an adjustment of dose may be necessary to ensure that an optimal dose is maintained.</p><p>&nbsp;</p><p>If more than four episodes of breakthrough pain are experienced per day over a period of more than four consecutive days, then the dose of the long acting opioid used for persistent pain should be re- evaluated. If the long acting opioid or dose of long acting opioid is changed the Abstral dose should be re-evaluated and re-titrated as necessary to ensure the patient is on an optimal dose.</p><p>It is imperative that any dose re-titration of any analgesic is monitored by a health professional.</p><p>&nbsp;</p><p>In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).</p><p>&nbsp;</p><p><u>Discontinuation of therapy:</u></p><p>Abstral should be discontinued immediately if the patient no longer experiences breakthrough pain episodes. The treatment for the persistent background pain should be kept as prescribed.</p><p>&nbsp;</p><p>If discontinuation of all opioid therapy is required, the patient must be closely followed by the doctor in order to avoid the possibility of abrupt withdrawal effects<em>.</em></p><p><u>Use in children and adolescents:</u></p><p>Abstral must not be used in patients less than 18 years of age due to a lack of data on safety and efficacy.</p><p>&nbsp;</p><p><u>Use in older people:</u></p><p>Dose titration needs to be approached with particular care and patients observed carefully for signs of fentanyl toxicity (see section 4.4).</p><p><u>Use in patients with renal and hepatic impairment</u></p><p>Patients with kidney or liver dysfunction should be carefully observed for signs of fentanyl toxicity during the Abstral titration phase (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Patients without maintenance opioid therapy as there is an increased risk of respiratory depression. Severe respiratory depression or severe obstructive lung conditions.
Treatment of acute pain other than breakthrough pain.

Patients being treated with medicinal products containing sodium oxybate.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Patients and their carers must be instructed that Abstral contains an active substance in an amount that can be fatal to a child, and therefore to keep all tablets out of the sight and reach of children.</p><p>&nbsp;</p><p>Due to the potentially serious undesirable effects that can occur when taking an opioid therapy such as Abstral, patients and their carers should be made fully aware of the importance of taking Abstral correctly and what action to take should symptoms of overdose occur.</p><p>&nbsp;</p><p>Before Abstral therapy is initiated, it is important that the patient&rsquo;s long-acting opioid treatment used to control their persistent pain has been stabilised.</p><p>&nbsp;</p><p><u>Opioid Use Disorder (abuse and dependence)</u></p><p>Tolerance and physical and/or psychological dependence may develop upon repeated administration of opioids such as fentanyl. Iatrogenic addiction following therapeutic use of opioids is known to occur.</p><p>Repeated use of Abstral may lead to Opioid Use Disorder (OUD). Abuse or intentional misuse of Abstral may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).</p><p>&nbsp;</p><p>Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.</p><p>&nbsp;</p><p><u>Respiratory Depression</u></p><p>In common with all opioids, there is a risk of clinically significant respiratory depression associated with the use of Abstral. Particular caution should be exercised during dose titration with Abstral in patients with chronic obstructive pulmonary disease or other medical conditions predisposing them to respiratory depression (e.g. myasthenia gravis) because of the risk of further respiratory depression, which could lead to respiratory failure.</p><p>&nbsp;</p><p><u>Increased intracranial pressure</u></p><p>Abstral should only be administered with extreme caution in patients who may be particularly susceptible to the intracranial effects of hyperkapnia, such as those showing evidence of raised intracranial pressure, reduced consciousness, coma or brain tumours. In patients with head injuries, the clinical course may be masked by the use of opioids. In such a case, opioids should be used only if absolutely necessary.</p><p>&nbsp;</p><p><u>Hyperalgesia</u></p><p>As with other opioids, in case of insufficient pain control in response to an increased dose of fentanyl, the possibility of opioid-induced hyperalgesia should be considered. A fentanyl dose reduction or discontinuation of fentanyl treatment or treatment review may be indicated.</p><p>&nbsp;</p><p><u>Cardiac disease</u></p><p>Fentanyl may produce bradycardia. Fentanyl should be used with caution in patients with previous or pre-existing bradyarrhythmias.</p><p><u>Elderly, cachectic or debilitated population</u></p><p>Data from intravenous studies with fentanyl suggest that older patients may have reduced clearance, a prolonged half-life and they may be more sensitive to the active substance than younger patients.</p><p>Older, cachectic, or debilitated patients should be observed carefully for signs of fentanyl toxicity and the dose reduced if necessary.</p><p><u>Impaired hepatic or renal function</u></p><p>Abstral should be administered with caution to patients with liver or kidney dysfunction, especially during the titration phase. The use of Abstral in patients with hepatic or renal impairment may increase the bioavailability of fentanyl and decrease its systemic clearance, which could lead to accumulation and increased and prolonged opioid effects.</p><p>&nbsp;</p><p><u>Hypovolaemia and hypotension</u></p><p>Care should be taken in treating patients with hypovolaemia and hypotension.</p><p>&nbsp;</p><p><u>Use in patients with mouth wounds or mucositis</u></p><p>Abstral has not been studied in patients with mouth wounds or mucositis. There may be a risk of increased systemic drug exposure in such patients and therefore extra caution is recommended during dose titration.</p><p><u>Abstral withdrawal</u></p><p>There should be no noticeable effects on cessation of treatment with Abstral, but possible symptoms of withdrawal are anxiety, tremor, sweating, paleness, nausea and vomiting.</p><p><u>Serotonin Syndrome</u></p><p>Caution is advised when Abstral is co-administered with drugs that affect the serotoninergic neurotransmitter systems.</p><p>The development of a potentially life-threatening serotonin syndrome may occur with the concomitant use of serotonergic drugs such as Selective Serotonin Re-uptake Inhibitors (SSRIs) and Serotonin Norepinephrine Re-uptake Inhibitors (SNRIs), and with drugs which impair metabolism of serotonin (including Monoamine Oxidase Inhibitors [MAOIs]). This may occur within the recommended dose.</p><p>&nbsp;</p><p>Serotonin syndrome may include mental-status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).</p><p>If serotonin syndrome is suspected, treatment with Abstral should be discontinued. <u>Sleep-related breathing disorders</u></p><p>Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep- related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.</p><p><u>Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs</u> Concomitant use of Abstral and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Abstral concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.</p><p>&nbsp;</p><p>The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).</p><p><u>Abstral contains sodium</u></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium- free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use of medicinal products containing sodium oxybate and fentanyl is contraindicated (see section 4.3). Treatment with sodium oxybate should be discontinued before start of treatment with Abstral.</p><p>&nbsp;</p><p>Fentanyl is metabolised by CYP3A4. Active substances that inhibit CYP3A4 activity such as macrolide antibiotics (e.g. erythromycin), azole antifungal agents (e.g. ketoconazole, itraconazole) or certain protease inhibitors (e.g. ritonavir) may increase the bioavailability of fentanyl by decreasing its systemic clearance, potentially enhancing or prolonging opioid effects. Grapefruit juice is also known to inhibit CYP3A4. Coadministration with agents that induce CYP3A4 activity such as antimycobacterials (e.g. rifampin, rifabutin), anticonvulsants (e.g. carbamazepine, phenytoin, and phenobarbital), herbal products (e.g. St John&rsquo;s wort (Hypericum perforatum)) may reduce the efficacy of fentanyl. CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction. Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline. Patients receiving fentanyl who stop therapy with, or decrease the dose of CYP3A4 inducers, may be at risk of increased fentanyl activity or toxicity. Fentanyl should therefore be given to patients with caution if administered concomitantly with CYP3A4 inhibitors and/or inducers.</p><p>Concomitant use of other CNS depressants, such as other morphine derivatives (analgesics and antitussives), general anaesthetics, gabapentinoids (gabapentin and pregabalin), skeletal muscle relaxants, sedative antidepressants, sedative H1 antihistamines, barbiturates, anxiolytics (i.e., benzodiazepines), hypnotics, antipsychotics, clonidine, and related substances may produce increased CNS depressant effects, increased risk of sedation, respiratory depression, hypotension, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).</p><p>Alcohol potentiates the sedative effects of morphine-based analgesics, therefore concomitant administration of alcoholic beverages or medicinal products containing alcohol with Abstral is not recommended.</p><p>&nbsp;</p><p>Abstral is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.</p><p>&nbsp;</p><p>The concomitant use of partial opioid agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) is not recommended. They have high affinity to opioid receptors with relatively low intrinsic activity and therefore partially antagonise the analgesic effect of fentanyl and may induce withdrawal symptoms in opioid dependent patients.</p><p>&nbsp;</p><p><u>Serotoninergic Drugs</u></p><p>Co-administration of fentanyl with a serotoninergic agent, such as a Selective Serotonin Re-uptake Inhibitor (SSRI) or a Serotonin Norepinephrine Re-uptake Inhibitor (SNRI) or a Monoamine Oxidase Inhibitor (MAOI), may increase the risk of serotonin syndrome, a potentially life-threatening condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of fentanyl in pregnancy has not been established. Studies in animals have shown reproductive toxicity, with impaired fertility in rats (see section 5.3). The potential risk for humans is unknown. Fentanyl should only be used during pregnancy when clearly necessary.</p><p>&nbsp;</p><p>Long-term treatment during pregnancy may cause withdrawal symptoms in the new-born infant.</p><p>&nbsp;</p><p>Fentanyl should not be used during labour and delivery (including caesarean section) since fentanyl crosses the placenta and may cause respiratory depression in the foetus or in the new-born infant.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Fentanyl passes into breast milk and may cause sedation and respiratory depression in the breast-fed child. Fentanyl should not be used by breastfeeding women and breastfeeding should not be restarted until at least 5 days after the last administration of fentanyl.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed with Abstral.</p><p>&nbsp;</p><p>However, opioid analgesics are known to impair the mental or physical ability to perform potentially hazardous tasks such as driving or operating machinery. Patients should be advised not to drive or operate machinery if they become dizzy or drowsy or experience blurred or double vision while taking Abstral.</p><p>This medicine can impair cognitive function and can affect a patient&rsquo;s ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine is likely to affect your ability to drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not drive until you know how the medicine affects you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is an offence to drive while under the influence of this medicine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, you would not be committing an offence (called &lsquo;statutory defence&rsquo;) if:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The medicine has been prescribed to treat a medical or dental problem and</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It was not affecting your ability to drive safely</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects typical of opioids are to be expected with Abstral; they tend to decrease in intensity with continued use. The most serious potential adverse reactions associated with opioid use are respiratory depression (which could lead to respiratory arrest), hypotension and shock.</p><p>&nbsp;</p><p>The clinical trials of Abstral were designed to evaluate safety and efficacy in treating patients with breakthrough cancer pain; all patients were taking concomitant opioids, such as sustained-release morphine, sustained-release oxycodone or transdermal fentanyl, for their persistent pain. Therefore, it is not possible to definitively separate the effects of Abstral alone.</p><p>&nbsp;</p><p>The most frequently observed adverse reactions with Abstral include typical opioid adverse reactions, such as nausea, constipation, somnolence and headache.</p><p>&nbsp;</p><p><u>Tabulated Summary of Adverse Reactions with Abstral and/or other fentanyl-containing compounds:</u> The following adverse reactions have been reported with Abstral <strong>and/or other fentanyl-containing compounds </strong>during clinical studies and from post-marketing experience. They are listed below by system organ class and frequency (very common &sup3; 1/10; common &sup3; 1/100 to &lt; 1/10; uncommon</p><p>&sup3;1/1,000 to &lt;1/100; not known (cannot be estimated from available data)). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>Adverse Reaction by Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>&sup3;</strong><strong> 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&sup3;</strong><strong> 1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&sup3;</strong><strong>1/1,000 to &lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from available data)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p><p>Paranoia</p><p>Confusional state</p><p>Disorientation</p><p>Mental status changes</p><p>Anxiety</p><p>Euphoric mood</p><p>Dysphoria</p><p>Emotional lability Disturbance in attention</p><p>Insomnia</p></td><td style="vertical-align:top"><p>Hallucination</p><p>Drug dependence (addiction)</p><p>Drug abuse</p><p>Delirium</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache</p><p>Somnolence</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Amnesia</p><p>Parosmia</p><p>Dysgeusia</p><p>Tremor</p><p>Lethargy</p><p>Hypoaesthesia</p><p>Sleep disorder</p></td><td style="vertical-align:top"><p>Convulsion</p><p>Depressed level of consciousness</p><p>Loss of consciousness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>Bradycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic </strong></p><p><strong>and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oropharyngeal pain</p><p>Throat tightness</p></td><td style="vertical-align:top"><p>Respiratory depression</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stomatitis</p><p>Vomiting</p><p>Constipation</p><p>Dry mouth</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mouth ulceration</p><p>Gingival ulceration</p><p>Lip ulceration</p><p>Impaired gastric emptying</p><p>Abdominal pain</p><p>Dyspepsia</p><p>Stomach discomfort</p><p>Tongue disorder</p><p>Aphthous stomatitis</p></td><td style="vertical-align:top"><p>Swollen tongue</p><p>Diarrhoea</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Skin lesion</p><p>Rash</p><p>Pruritus allergic</p><p>Pruritus</p><p>Night sweats</p><p>Increased tendency to bruise</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Musculoskeletal stiffness</p><p>Joint stiffness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders </strong></p><p><strong>and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fatigue</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>*Drug withdrawal syndrome</p><p>Asthenia</p><p>Malaise</p></td><td style="vertical-align:top"><p>Flushing and hot flush</p><p>Peripheral oedema</p><p>Pyrexia</p><p>Neonatal withdrawal syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Accidental overdose</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fall</p></td></tr></tbody></table><p>* <em>opioid withdrawal symptoms such as nausea, vomiting, diarrhoea, anxiety, chills, tremor, and sweating have been observed with transmucosal fentanyl</em></p><p><em>&nbsp;</em></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp; &nbsp;<strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_3"
 o:spid="_x0000_s1026" style='position:absolute;margin-left:-2pt;margin-top:5.3pt;
 width:467.35pt;height:153pt;z-index:251660800;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f"/><![endif]--></p><ul><br /><li>The National Pharmacovigilance Center (NPC)</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: + (966-11) 2057662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at: + (966-11) 2038222, Exts: 2317-2356-2340.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><o:wrapblock><v:group id="Group_x0020_18842"
  o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
  margin-left:59.3pt;margin-top:702.1pt;width:.65pt;height:36.65pt;z-index:251660288;
  mso-position-horizontal-relative:page;mso-position-vertical-relative:page'
  coordsize="8382,465582" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA4YlQPp8CAAD2BgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzEVdtunDAQfa/Uf7D8nsDSvZBVSKSm
bV6qdpVNPsAxZkE1NrK9hP37jm9A0ySq2ofygAfPzJnbwb68HlqOeqZ0I0WBF+cpRkxQWTbiUOCH
+y9nOUbaEFESLgUr8IlpfH31/t0l2R4U6eqGIkAQeksKXBvTbZNE05q1RJ/LjgnQVVK1xMCnOiSl
Ik+A3PIkS9N10pJG4KsJ6hMxBB1V8xdQXNIfrLwhoicaIDndzndCjpz+OzLZiv5Wdftup2zm9Fu/
U6gpCwydE6SFFuEkKIIZfCbPvA4TwFCp1trLqkJDgTerbLlZYXQqcH6xWK83qYdjg0EU9Hm2Ai0F
9XK9WoLsg9Xf33an9ec3ACA9nwYIs9ScaHN7peJFni+zWPWtkscO+a3/2ACYAvQmNG1W9YccMg1t
W4Hsh/JS1brzJf8+4SzLc2i+n/K+Jh1DfivWa108sOijuw5EeTbnX/KMw71YLJevZglcO2pzy6Sj
C+m/auPiHsookTpKdBBRVIwaxB09jXsr934cm9QRY/1s0VZETwX2edSOY7ZZVtfKnt1LZ2UsUWcF
AGsmLRdzK48UJwKGUR3XzoGNZkDqaTrRJq7e1gf+Y0NHhTEwCLZI90eOhcPmvLVc2B5AGEq6Alec
GN+AxjCFeNPCMZlt0nQCdmhxzmbYOwKZ4aMsT7Zfj7A6XkD12uzNiTM3OGfGRLkjitzBIcKJPXOZ
OHvYB3qCBeQ2IR0123d3MFBPshhKW0gbiYs7VsFh5MZjN7Q6PN5whXpiGeAeVwvhXU3CbogVTF1E
h2P9q4bzEXLhXF+C9OkEY+vHqgqyHD1T70lDNp6BUCv0OPIQ6hydXGQpJn8BV09M09cK5vY/hSUc
UsmzEz/o3A1lr5X599VPAAAA//8DAFBLAwQUAAYACAAAACEAkn2H4B0HAABJIAAAGgAAAGNsaXBi
b2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2xZL1iI3JgyXLcxC9ESoocKYnaZcxd
LkjKjm5FcuqlQIG06KEBeuuhKBqgARr00h9jwEGb/ogOuS9SouIHXCAobAHG7uw3w+HM7Mzs8M7d
ZxH1jjEXhMVtv3qr4ns4HrExiYO2/2iw/dlt3xMSxWNEWYzb/gwL/+7Gp5/cQesjSpIhQ3w8CHGE
PRAUi3XU9kMpk/WVFTECMhK3WIJjeDZhPEISbnmwMuboBBaI6MpqpdJciRCJ/Q2QKJWgHoV/sRSK
MKK8r8RgL0YRrH4wmZAR1tjxUVUhxEx0KfeOEW37IHPMTgb4mfQ9ioSEB22/ov/8lY07K2g9Y6Jy
Ca/Bt63/Mr6MYXy0qtfkwbBYtF5v1JubhXwNoHIR12v1mr1mIU8D0GgEO011sWW2Vrv1DGuA0kuH
7K3WVq1q4Q35tQWdNxvqZ+E1KJVfX8Bvb3fBihZeg1J8YwHf6Kx1tmz5GpTimwv4VmVzq96y5GtQ
SEl8tICuNJq1br7bAjJhdMcJX2vUt1urmfASBdFQRJdaYsJiuSzWIvSU8W0AKCBFksSenCV4gkYQ
k11EyZATb5cEIQRegmImgFxZrWxXavBf/er6SnsUrWNkcCu9QBOxQFL6eGLESSLb/n2Q6huQs7dv
T5+/OX3+++mLF6fPf83W1qIsvh0UBybf+5+++efVl97fv/34/uW36dLzeGHi3/3y1bs//vyQeNhx
aYqz716/e/P67Puv//r5pUP6JkdDEz4gERbePj7xHrIINujQHw/55TgGISImx2YcCBQjtYpDfk+G
Fnp/hihy4DrYtuNjDqnGBbw3fWop3A/5VBKHxAdhZAH3GKMdxp1WeKDWMsw8mMaBe3E+NXEPETp2
rd1FseXl3jSBHEtcIrshttQ8pCiWKMAxlp56xo4wduzuCSGWXffIiDPBJtJ7QrwOIk6TDMjQiqaS
aYdE4JeZS0Hwt2Wbvcdeh1HXrrfwsY2EdwNRh/IDTC0z3kNTiSKXyAGKqGnwXSRDl5L9GR+ZuJ6Q
4OkAU+b1xlgIF88Bh/0aTn8Aacbt9j06i2wkl+TIJXMXMWYit9hRN0RR4sL2SRya2M/FEYQo8g6Z
dMH3mP2GqHvwA4qXuvsxwZa7z88GjyDDmiqVAaKeTLnDl/cws+K3P6MThF2pZpNHVord5MQZHZ1p
YIX2LsYUnaAxxt6jzx0adFhi2bxU+n4IWWUHuwLrPrJjVd3HWGBPNzeLeXKXCCtk+zhgS/TZm80l
nhmKI8SXSd4Hr5s270Gpi1wBcEBHRyZwn0C/B/HiNMqBABlGcC+Vehgiq4Cpe+GO1xm3/HeRdwze
y6eWGhd4L4EHX5oHErvJ80HbDBC1FigDZoCgy3ClW2Cx3F+yqOKq2aZOvon90pZugO7IanoiEp/b
Ac31Po3/rveBDuPsh1eOl+16+h23YCtZXbLTWZZMdub6m2W4+a6my/iYfPxNzRaaxocY6shixrrp
aW56Gv9/39Mse59vOpll/cZNJ+NDh3HTyWTDlevpZMrmBfoaNfBIBz167BMtnfpMCKV9OaN4V+jB
j4DvmfE2EBWfnm7iYgqYhHCpyhwsYOECjjSPx5n8gsiwH6IEpkNVXwkJRCY6EF7CBAyNNNkpW+Hp
NNpj43TYWa2qwWZaWQWSJb3SKOgwqJIputkqB3iFeK1toAetuQKK9zJKGIvZStQcSrRyojKSHuuC
0RxK6J1dixZrDi1uK/G5qxa0ANUKr8AHtwef6W2/UQcWYIJ5HDTnY+Wn1NW5d7Uzr9PTy4xpRQA0
2HkElJ5eU7ou3Z7aXRpqF/C0pYQRbrYS2jK6wRMhfAZn0amoF1Hjsr5eK11qqadModeD0CrVaN3+
kBZX9TXwzecGGpuZgsbeSdtv1hoQMiOUtP0JDI3hMkogdoT65kI0gOOWkeTpC3+VzJJwIbeQCFOD
66STZoOISMw9SqK2r7ZfuIHGOodo3aqrkBA+WuXWIK18bMqB020n48kEj6TpdoOiLJ3eQoZPc4Xz
qWa/Olhxsim4ux+OT7whnfKHCEKs0aoqA46JgLODamrNMYHDsCKRlfE3V5iytGueRukYSumIJiHK
KoqZzFO4TuWFOvqusIFxl+0ZDGqYJCuEw0AVWNOoVjUtqkaqw9Kqez6TspyRNMuaaWUVVTXdWcxa
IS8Dc7a8WpE3tMpNDDnNrPBp6p5PuWt5rpvrE4oqAQYv7OeouhcoCIZq5WKWakrjxTSscnZGtWtH
vsFzVLtIkTCyfjMXO2e3okY4lwPilSo/8M1HLZAmeV+pLe062N5DiTcMqm0fDpdhOPgMruB42gfa
qqKtKhpcwZkzlIv0oLjtZxc5BZ6nlAJTyym1HFPPKfWc0sgpjZzSzClN39MnqnCKrw5TfS8/MIUa
lh2wZr2Fffq/8S8AAAD//wMAUEsDBBQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAY2xpcGJvYXJk
L2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIwEITvgu8Q9m7SehCRJr2I0KvU
BwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFBp7yenOFw6y+7I5CUpdNy9g45LJig
FdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKjYUGquzTI9lV1YPGTAeKLSTrNIXa6
BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2BiYZ9/SbeAAAA//8DAFBLAQItABQA
BgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1s
UEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAANgEAAF9yZWxzLy5yZWxz
UEsBAi0AFAAGAAgAAAAhAOGJUD6fAgAA9gYAAB8AAAAAAAAAAAAAAAAAIAIAAGNsaXBib2FyZC9k
cmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEAkn2H4B0HAABJIAAAGgAAAAAAAAAA
AAAAAAD8BAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAnGZGQbsA
AAAkAQAAKgAAAAAAAAAAAAAAAABRDAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcx
LnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAAFQNAAAAAA==
">
  <v:shape id="Shape_x0020_22885" o:spid="_x0000_s1027" style='position:absolute;
   width:9144;height:465582;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9144,465582" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDzJOpuwwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heUJvujFUSVNXKZGCVzXQ6yP7mgSzb0P2NcZ/3y0UPA4z8w2zO0yuUyMNofVsYL1KQBFX
3rZcGyivn8sMVBBki51nMvCgAIf9fLbD3Po7n2m8SK0ihEOOBhqRPtc6VA05DCvfE0fv2w8OJcqh
1nbAe4S7TqdJstUOW44LDfZUNFTdLj/OwLUsJb25tRRjEr6Op7Z4fbOFMS+L6eMdlNAkz/B/+2QN
pGmWbeDvTrwCev8LAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA8yTqbsMAAADeAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,l9144,r,465582l,465582,,e" fillcolor="black" stroked="f"
   strokeweight="0">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,9144,465582"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page" anchory="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1" height="49" src="file:///C:/Users/ralnahdi/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>The symptoms of fentanyl overdose are an extension of its pharmacological actions, the most serious effect being respiratory depression, which may lead to respiratory arrest. Coma is also known to occur.</p><p>Management of opioid overdose in the immediate term includes removal of any remaining Abstral sublingual tablets from the mouth, physical and verbal stimulation of the patient and an assessment of the level of consciousness. A patent airway should be established and maintained. If necessary, an oropharyngeal airway or endotracheal tube should be inserted, oxygen administered and mechanical ventilation initiated, as appropriate. Adequate body temperature and parenteral fluid intake should be maintained.</p><p>&nbsp;</p><p>For the treatment of accidental overdose in opioid-na&iuml;ve individuals, naloxone or other opioid antagonists should be used as clinically indicated and in accordance with their Summary of Product Characteristics. Repeated administration of the opioid antagonist may be necessary if the duration of respiratory depression is prolonged.</p><p>Care should be taken when using naloxone or other opioid antagonists to treat overdose in opioid- maintained patients, due to the risk of precipitating an acute withdrawal syndrome.</p><p>&nbsp;</p><p>If severe or persistent hypotension occurs, hypovolaemia should be considered, and the condition should be managed with appropriate parenteral fluid therapy.</p><p>Muscle rigidity interfering with respiration has been reported with fentanyl and other opioids. In this situation, endotracheal intubation, assisted ventilation and administration of opioid antagonists as well as muscle relaxants may be requested.</p><p>Cases of Cheyne Stokes respiration have been observed in case of fentanyl overdose, particularly in patients with history of heart failure.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Analgesics; Opioids; Phenylpiperidine derivatives. ATC code: N02AB03</p><p>Fentanyl is a potent &micro;-opioid analgesic with rapid onset of analgesia and short duration of action. Fentanyl is approximately 100-fold more potent than morphine as an analgesic. Secondary effects of fentanyl on central nervous system (CNS), respiratory and gastro-intestinal function are typical of opioid analgesics and are considered to be class effects. These can include respiratory depression, bradycardia, hypothermia, constipation, miosis, physical dependence and euphoria.</p><p>&nbsp;</p><p>Opioids may influence the hypothalamic-pituitary-adrenal or &ndash;gonadal axes. Some changes that can be seen include an increase in serum prolactin, and decreases in plasma cortisol and testosterone. Clinical signs and symptoms may be manifest from these hormonal changes.</p><p>&nbsp;</p><p>The analgesic effects of fentanyl are related to the blood level of the active substance; in opioid-na&iuml;ve patients, minimum effective analgesic serum concentrations of fentanyl range from 0.3-1.2 ng/ml, while blood levels of 10-20 ng/ml produce surgical anaesthesia and profound respiratory depression.</p><p>&nbsp;</p><p>In patients with chronic cancer pain on stable maintenance doses of opioids, statistically significant improvement in pain intensity difference was seen with Abstral versus placebo from 10 minutes after administration onwards (see figure 1 below) , with a significantly lower need for rescue analgesic therapy.</p><p>&nbsp;</p><p><em><u>Figure 1 Mean Pain Intensity Difference from baseline (&plusmn; SE) for Abstral Compared with Placebo</u> <u>(measured by a 0-10 Lickert scale)</u></em></p><p><em>&nbsp;</em></p><p><img alt="" width="730" height="440" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAtoAAAG4CAYAAAB7OkD/AAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAEMSSURBVHhe7d1PyF3VmudxNRqjMcZcb0gqAb25wS5prNsOQog1SOGgCTjIRa4QoZo0LQidgShcwSZ3kIGQtAiRuiAJQiE4CTgJDkKokYMMMjQ1yuileuYkUMM7PO135zyv613vPv/3Omftc74fWOQ9+/zN3vvs/XvX++y1nhhIkiRJ6pxBW5IkSSrAoC1JkiQVYNCWJEmSCjBoS5IkSQUYtCVJkqQCDNqSJElSAQZtSZIkqQCDtiRJklSAQVuSJEkqwKAtSZIkFWDQliRJkgowaEuSJEkFGLQlSZKkAgzakiRJUgEGbUmSJKkAg7YkSZJUgEFbkiRJKsCgLUmSJBVg0JYkSZIKMGhLkiRJBRi0JUmSpAIM2pIkSVIBBm1JkiSpAIO2JEmSVIBBW5IkSSrAoC1JkiQVYNCWJEmSCjBoS5IkSQUYtCVJkqQCDNqSJElSAQZtSZIkqQCDtiRJklSAQVuSJEkqwKAtSZIkFWDQliRJkgowaEuSJEkFGLQlSZKkAgzakiRJUgEGbUmSJKkAg7YkSZJUgEFbkiRJKsCgLUmSJBVg0JYkSZIKMGhLkiRJBRi0JUmSpAIM2pIkSVIBBm1JkiSpAIO2JEmSVIBBW5IkSSrAoC1JkiQVYNCWJEmSCjBoS5IkSQUYtCVJkqQCDNqSJElSAQZtSZIkqQCDtiRJklSAQVuSJEkqwKAtSZIkFWDQliRJkgowaEuSJEkFGLQlSZKkAgzakiRJUgEGbUmSJKkAg7YkSZJUgEFbkiRJKsCgLUmSJBVg0JYkSZIKMGhLkiRJBRi0JUmSpAIM2pIkSVIBBm1JkiSpAIO2JEmSVIBBW5IkSSrAoC1JkiQVYNCWJEmSCjBoS5IkSQUYtCVJkqQCDNqSJElSAQZtSZIkqQCDtiRJklSAQVuSJEkqwKAtSZIkFWDQliRJkgowaEuSpF47efLk4IknntjVbt26NXzE9OK1+HeSS5cubb/X1tbWcOlj3I77eFxu3HNT3H/v3r3hLfWNQVuSJPUeoToNxxFkZwnb586dG3zxxRfNzzyP26PwuLg/QnUqDch8lnhdTHpu4DEG7X4zaEuSpN7LgzYIqePCcoowmwdeXm9UyM0DcBqm0yCNPEyPe27gNv+n/LHqF4O2JEnqvbagzW0CbwTWUY1Qm4djcDsPwGgL5enz257H43nepOeCx7AsArpBu78M2pl8Z5ckSfXLgzbn8wjR06BXmZZqW4a2UJ8u419up2LZpOcicohBu/8M2on4LdOgLUlSvxBWOYenbdqQjVqCdppBDNr9Z9BOsHPzhZo1aL/55pu7vtwskyRJy9EWYAP35efptBHI2/6ize22sB4dc6n0+W3P4/E8b9xz47621vY5VD+D9lB8OeYJ2i+99FLrl8KwLUnScowL2tMg5ObP5zbL23Cep8c5kB8iDPNv2hPedjHkqOem7NHuP4P2L9i5YyeeJ2jn+FJEkyRJ5S0atMH5n9cB2WBcHkjDdPREp7gdYZrXSYP0pOcGg3b/bXwSZOdNd36DtiRJ/ULATs+9EZbnEa+Vh3ayQX5eJzPEe6Y91IiQTItQnRr33GDQ7r+NT4LxxWlr8+riNSRJktRvJsGMPdqSJEnqgkkwY9CWJElSF0yCGYO2JEmSumASLMCgLUmSJJNgAQZtSZIkmQQLMGhLkiTJJFiAQVuSJEkmwQIM2pIkSTIJFmDQliRJkkmwAIO2JEmSTIIFGLQlSZJkEizAoC1JkiSTYAEGbUmSJJkECzBoS5IkySRYgEFbkiRJJsECDNqSJEkyCRZg0JYkSZJJsACDtiRJkkyCBRi0JUmSZBIswKAtSZIkk2ABBm1JkiSZBAswaEuSpJLSrNHWVAe3RAHu6JIkqaSXXnppR95IG/epDr1Igl988cWOHQgPHjwYXL58ufm5NvlnlSRJKsXMUa9ebJVDhw4N7t271/wcO9KjR4+q3alih3enlyRJpZk56tWboH3z5s0mbLMj3blzZ3Dq1Klqd6rY4d3pJUlSaWaOevViqxCy0/AazdIRSZK06cwc9erNVrl169Z2L/bJkyebuu1axQ7vTi9Jkkozc9TLrVKAQVuSJC2LmaNevdgq9GZfuHBheOuxS5cuNSOP1MigLUmSlsXMUa9ebBVKRbggMsWoI+fOnRveqotBW5IkLYuZo1692CrsPATrFCOP1LpTxQ7vTi/Vi1/g0+9qNP6CNqt4Lf6dhL/GxXttbW0Nlz7G7biPx+XGPTe9r+25ktZXfPdVn15sFU5e9F5zASSNMhJ2qGlOaqsQO7w7vVQ3QnV6HImwOkvYjmMTeN64v7TxuLg/QnWK2zFnAJ8lveh73HO5Lz5z3Jc+V9J64zufH09Uh15sFU48lI7EjhRtnp6nZUg/o6R65UEbfG/HheVUjO2f4vUiLOd4bHpfGqbTII08TI97bn4s5L5p/w+S+o/jQ34sUh16s1U46TBuNicP/h11IqtB7PDu9FLd2oI2tznOcF/6Xc4bITcPx+B2BOBUWyhPn9/2PB7P8yY9N8d9hG1JmyGOS6pPr7dK28msBrHDu9NLdcuDNscUvrfTHlsIs3mgbVuGtlCfLuNfbqdi2aTn5gjgdE5IWj+3b98evPnmmztaZI58+dWrV4fP0qr0IgmmvdlpqzXIxg5f6+eT9BhhNf2+0mb5Bb7GoE3vd62dEJIW9/TTT+86bo1qe/bsGfz888/DZ2oVepEEOZm07UC0GtX++SQ9NiqsgvvS73LeCLM0fulPcbst6C6rdKRtmaT1EcegadrevXsH//Ef/zF8plahF0mQCyHp0ebEkjZ2ohqlO7mkeo0L2tMgAOfP5zbL23BMSEs66PnmWAb+TXvC2y6GHPXcsMj/RVI/RL6Ypr3wwgsG7RXrRRIkZLfNAllrz026k0uq16JBGxyHeB0QfMcdl9Iw3dZLze0I07xOGqQnPZf/RxrE+UyjAr+k/qD048cffxzcuHFjcOXKle18MU0zaK9eL5Jg284TrUa1fz5Ju0vSIizPI14rD+2E5fw4QFiO90yDMaIXm5b2boe256bPSduiv0BIWp6ffvqpCdME6U8//bS5kPHEiRPNd/n5558fvPTSS82/+fd8UjNor55Bu4DaP58kSVqev/3tb02QZsQQwvR7773XhOkXX3yxyQoHDx5swnSaH7poBu3V603Q5k+geWN5jdKdXJIkrT8CbVricebMmSZMkwUYKYQgTaBOM8K4Fj3ZhGVuHzt2bPv1pm0G7dUzCRaQ7uSSJGk93L9/f1eJBwE4Qu2sJR7Rkx1D9vF6b7/9dvP6BHbeKw/K+WuMawbt1etFEnz06FFzIVDUQYILJFleo3QnlyRJ/fCf//mfTbjlmo20xOO5555rzumEYlp6nh/X8p5sSkV4vYsXLzavTykJ70dpybTy9xjXGEfboL1avUiCXADEEH/phUWE7HFX969SupNLkqR6PHz4sAm3X3311a4Sj2effbYJxlE7PU3Le7K5iJHX47WvXbvWvBcXO3bl8OHDuz7DqPbqq6/OFOLVvV4kQXaW6L3mZzDcX/xcm9jBa/18kiStM0o87t6924RdOusIvlHiQYgmGBOq0/P1uMbjafxMLzWv98477zSv/+233zZhelkzMMZwf2mLz5kvp4deq9WLJEjJyIULF5ryEXYkykbo4abVKHZ4miRJ6laUeBByCbuEXsLvvCUeeU/2b3/72+b1COm8PqGd96tV/D9Un15slRhhJG+LjHtbUvoZJUnS7PISD4Lv66+/3pxbIxjHiBzTtLwnm9eibITX5j14L96zj+L/qPr0ZqswKQM92dRl8xsm4btWscO700uSNBrhNko8uECQME1vMufPRUs86N1OSzzonOP91rGcIv7/qk8vtgplI7S+iB3enV6StMminjhKPBi6jvAbw9mlwXiaNmps6Sjx4L2oz940sX5Un15sFWqx+RL1Rezw7vSSpHUX04czwgZhl+CbTx8+S4lH29jSUeIxamzpTRfrTvXpxVbhzz2MMpLj4sgaxQ7vTi9J6rt8+vAo8YgLB/NgPKmNGluaMat5/XnGlt50sW5Vn15sFeqyGXkkxtKOVutOFTu8O70kqQ/oISbcxvThaYlHHoynaaPGlmY2xRJjS2+6WO+qTy+2SuxAba1GtX8+SdLmiRIPgnRMHx4lHnkwnqbxeBo/E8Z5vZg+fNljS2+62CaqT2+CNqOM5K3WnSp2eHd6SdKyRIlHPn14XuKRnqPGtVFjS8f04bWPLb1JYpupPm6VAmKHd6eXJHUpL/FIpw+PEo8IxtO06MlOx5bm9Xjtvo8tvUlie6o+vdkq9GAz8gi12bh582bzb41ih3enlyTNiuHpCLiEXc57BN+YPnzREo98bOko8XCq7n6Lba369GKrxNTr6Y7EKCRMYFOj/LNKkhRi+vC8xGPR6cNjCL18bGlKPDZxbOlNEvuC6tOLrcJoI/RoI3akR48eVbtTxQ7vTi9JmymfPpwSj3z68FlKPHgsz6E8hNsE6Xz6cMeW3iz5PpI31aE3QZtSkbgA8s6dO4NTp05VuyO5o0vS+iPcxvTheYlHBONZpw8fNbZ0TB/u2NIK7C/5PhSN+1SHXiRBQnbbjmTpiKS+I0ylx4y8cb9WI0o8Yvpw6prZHvOWeMQsiW1jS/P6vJdjS0vrpdokSK91esEjv81HLzaT13Q5K+TW1taOg+GiunwtSettUlCzZ6qsKPFIpw/PSzyi9nmalg6hl48tHdOHO7a0tDmqTYKUi3CgQtRn50YtnxXBPfDnP9oi0oOuJE3L40YZhNso8YjpwxkTmnWd1z5PavkQevnY0jF9uCSh2iM6B7D8AsjcqOWzoDc7Rc+5QVvSKnjcmA89xITbKPFIpw9nfRKMo5d5mpYPoZeOLR3Thzu2tKRpVHtEZ7zs/ODX1roUJSSz4gCcf65okjQtjxujxfThBN18+vCofZ6lxCMN36PGlrbEQ9Kiqj2iM042JR35wTFvXUmD/azG9ZRI0rQ2+bgR04dTepGWeESJRtQ+T1vikQ+h1za2NO8nSSVVe0RPL4bkINlm1PJFRLhfBM+PJknTWvfjRj59eJR48H+O2ucY3m6aFvXVMYQer5WPLW2Jh6RVqvaIvsyLIVNRPpLXbs8iTgLx+SVpGutw3EinD89LPBadPpxgzevlY0s7fbikWlV7ROeguoyLIdvwugZtScvWh+NGlHjk04dHiUYajKdpeX1129jSTh8uqa+qPaKv4mJIMD63o45IWoVajhtR4pFOH0745bPlw9tN09L6ahqvlY8t7fThktZRtUlwWRdD0iuTvl4XE+GkrydJo8RkKdHiuJEuo5UY/SIt8aBzgfAb04dHice004fn9dWjxpZ2+nBJm6YXSZADd5tRy1ctTj61fj5Jq3f58uXBnj17tksnaHHciNs0QiyBl6A6i5g+PEo8Fp0+PK+vjhIPXjvGlnb6cEnaqddJsMTFkF1IT06S1IaQmh4rJjUCbS56xNMSj3z68FlKPNLwHSUeji0tSfOrNgnSC0MD5RxtjZNBjdITlyS1mTVo/9M//dN2iUc+ffi0JR55+I4SD8eWlqQyqk2CcWJIf25rNar980lavVmD9rQtD9/0cDu2tCStRrVJkAlraOBkYY+2pHWySNBOSzxi+nDHlpak+vQiCS5zwpoupCdESWoza9A+evSoY0tLUs9UnwSZOIbe6wsXLjRja/PzIpPJLEN6cpSkFEPccWEhFxumx4pJjYAtSeqXqpNgPsZ12uJCyRqln1OSQCnH559/PvjNb36zPQviLM2gLUn9U20SpCyk7WSTNktHJNWO4fA+/PDDpqZ63759O44PszSDtiT1T7VJkFKRQ4cODW7evLmjVOTRo0dNbzb38ZgapSdHSZuJKcW5QJEJXvIyEXq0ZxnfmmbQlqT+qTYJEqTHlYfQm81japSeHCVtFi5SfPvtt3eVh9CbTbhmWnJC+HfffddcEJm2eGy+nEljHEVEkvqn2iTIyWaSaR6zCnGyrPXzSere7du3m1Acw+5F279/f7Pss88+mziroscNSVovVQftdMzsvF2+fLnaE1KcLD1hSuuPEUROnDgxOHjw4I7vfpSHfPnll1P3RnvckKT1UnXQnqbVqPbPJ2kxDNFHgGYK87xEhMB97NixJoDPyuOGJK2XqoP2yZMnm7Gz29qpU6eqPSHFydITprReKP2gBOTAgQNNSUj6Xac8hOnOKSGZl8cNSVovVQdtRhgZhftqPSHFydITprQeuHiRIfooBcmH6GMZFz8yW+OiPG5I0nqp9og+zRjZjqMtqaSffvqpGaKP8pB0iD5+Ztg+7nv48OHw0YvzuCFJ68UjegFxsvSEKfUTvdNnzpzZdYEjvdmUjNC7PWkEkXl43JCk9eIRvYD0xCypP6ivps46H6KP3mumTqc+u+R41h43JE0rPUa1NdXBLVGAO7rUH4wgwgghjCDSNkQfy2/cuNE8rjSPG5KmlXcIpI37VIdeHNEZN7tP0p1dUp3omf7888+bnup8iD5OUoyNPc8QfYvwuCFpHh476tWLrcLOc+nSpcHW1tZwSd1ih3enl+pDbfUnn3zShOl8BBF6tJnd8e7du8NHL5fHDUnz8NhRr15sFcbNxp07dwY3b94c3Lp1q7ldq9jh3emlejBEH6OEMBxfOoIIjR5thuhjlJFlI9innyVv3C9J48TxQvXp3VYhZDORzaFDh5pp2Gvs5U5PkpJWi/BMiM7LQwjbhG7CNyF8VcbVWdKstZQ0SRwvVJ9ebBV2HnqyCdexMxG2Cd30chO4axKfkSZpNSj/oDc4v8CR4fkIr5SPlBiiT5KWzcxRr94E7WiUkeQT1dQ2cU36eSUtFxcwciFj3lNMjzYXPn755ZdFh+iTpGUzc9SrN0H71KlTgwcPHgyX7FTbzhU7vDv98vGXjnT9R5unrj9ei38n4WLdeK+8nInbcR+Pa8N9o0bXYTn3azSG3iNAMxRfXiJCjzbLCeDLGKJPkpYtjneqTy+2Cr3Yjx49Gt7ajfKRmqQneS1f1PGHCMGzhG32uQi+PC8uyG3D4+L+CNUpbsdfXfgsaaBmeewrbUGb1437tRs900wiQ081JSGxrmj0aDP5DJPQSNI68zxRr15slbadh7rsUT3cqxY7vDv9auRBG2yLcWE5FeE3xeuNKlHisel9aZhOQzjagjh4/bagDf4/7ks7cfEi06ATrtuG6GP6dKZRl6RNEMc/1afarULoiMbOk96OxsWRNYod3p1+NdqCNrcJvBFaR7XYt/JQzm2W59pCefr8tufx+Dy0G7Sn8/Dhw2aUEMpD0iH6+Jll3LeKIfokaZXiWKj6VLtV6PkjpMTO09YM2mqTB20CLNtiVJDN0SOd11K3LUNbqE+X8S+3U6OWGbRHo3eaIfoYji/9ftGbzTJ6t1c5RJ8krcoPP/ywfUxUfarfKgzrx85D6M7bqD/lr1rs8O70qxHBNG3ThmwYtOtBfTV11vkIIpSMHDhwoKnPdog+SZvq66+/3nEBONnIi77r0ouzdx5KapcGAi1fGnRzEVpHNcIujYNVitttQdjSkTIYIYSRQvIxsDmhsJwRRjyZSNpkH3/8cdPh8OSTT24fI5966qlmlDaHMK1HtWdvLnSMix0JJW2NnapGscPX+vnW3bigPQ32rfz53GZ5G7ZzOqQfPd8Rmvk37Qn3YsjRODEQoCkFaRui79ixY00Al6RNd/78+cHzzz+/I2Snjb8EWk5Xh2rP3tRfRw12204UrUa1f751t2jQBj3RvA4IwHkPdyoN022/AHI7gvionvFNDtqUfjBLI+UhbUP0MbujQ/RJ0uM5A06fPj145plnRoZsGve9+uqrXhxegWrP3gzfF1Ors9MQUPLG8hqlO7uWi8Carv8Iy/OI18pDe9u+R9CO90x7txG92LS8zju9j8Zrp9LXpY3qVe8jelsuXrzY9GCnI4jQ6NHm4sf79+8PHy1Jm42/+r322muDPXv27DhejmqUkRw5csShTlesF0lwVE/fqOWrlu7oknaih+Wdd97ZVR5C2OZPoQzR5588JW0yjoF3794dXLlypWl0POQdEtM0wjbBnKFRtRq9SIL04kVPHjNEMhIJbdxskauU7uSSHuOkQRlIfoEjQ/RRIsIQfY4gImldcXyjd3nShYpXr15tOiLy0ZbmaYRsynA9tq5OL5IgOwtX0eLChQvbO1D+Z/ZaxOejSZuO8p0TJ07sOmnQe83U6Z9//rlXyEvqNXqMCdFcTxK90HQs0GL8f455HAcJvuN6mJnZNj1WRuP51Ga33dfW6M3m2OtfCFerN0GbWtY7d+40P1MyQm82P9codvJaP59UGhfs3LhxoxmKL59khtss536H6JPUFxyzCNBcOxMhOso5OK4RovO/2I1qXJ8yCsGYsB3vwWN5X96fMP/HP/6xGdZvVK02F0ISst944w07MSrQm6BNrxi/BcaFaQTvuFiyNukOL20SDupMIkNPNb0v6XeBkxC9K4tcoCpJXeEXfYIrbVKvL6E1P6ZN2yKEx1/1CM+L9jJfv369eb28bpuATa/32bNn7cioRC+SID3Y7EAE7Rhbm1ISg7ZUB+r/qLFmeD5qrtPvAD08nFg4mUnSMkQ9dH5BIcci/qLGsYmQGgF4XB0zHQgRktMWddTpfYz3z3vQIx3vS+cCn6XrUZS+//77wcsvv7wjbHMMfv/994ePUA1MggXEDk+T1hl1howSQk9P3rPCSYjRRRzHVVIJBONr1641YZZwS3vuueea40/UQ7cF5LbG8WrceP0E5SjniADNBFolAvQseO/4xYFWawfkJutNEqQmO0YficZOVaPY4Wv9fNKiOLnQO5TXX9ObzTJqCr0AR9Is0gsKCbHj6osJ2ZSo5b/gT9P4KxsBPI5fvMZHH300fOX+Yb3F/0316cVWidKRtlaj2j+fNC9OgPTo5L1E/LmSZdRnj/rzq6TNRc8rIZoATW/wpAsK6WFmGvFReL38F30az6dFPTWPifeJnmiOY3yWcSN/9E38/1WfXmyV2IHaWo1q/3zSrDg5UnuYX1HPyZAT2ZdffunV7ZKaEEs5GcGWoBzHigjAHDPSY8i4xl/Ixl3Qx3GJ9+GvaxGiCdC0TfuFP9aZ6tOLrcKFj22T0ziOtlQOwZkATZDOT44EboI3JzpJ64mwSmiNCwonDcnJ8YC/bqXHimla9GSnPdTUQ/Pemk6sN9WnF1uFSWpolJCkrdadKnZ4d3r1ESdXSkA48eUnTZbRSzXuoiFJ9Yt6aEbEiN7gKLEYdUEhy8d1cPGL+bPPPrvrmEGLX9Z5jXifeN8YlWOdSjmWLda36tOLrRI7UFurUe2fT2rDxYtcxEivUj5EH8v486w9TFK/xNj2EW7T7zQBOO1FnqbR0zzOV199tWNoO3rDOW54cXRZsX1Un94EbX6LzlutO1Xs8O706gOG32MYvrw8hAuUWEa9pT1N5aThp61xv4T8gkLapPItvtt5L/OkFr3Q+QWFHAu8FqNOse1Un15sFcpE2oxavmqxw7vTq2acsOl5yi9wpDebkhEmoLEXqjwCTbr+88b9Wm/pDIX0CBOgp72gkFKMv/71r8NX2u3dd9/dDtr8G68RI33EBCteUNhvsT+oPr3ZKlwMSR1XhGvG0a5V7PDu9KoR3yOmQudkm+6rhGvGpeXPzPZarYbHjc1AzzTBlpDL9ib0RgCetfeZXudxvdqE+Ajv/Bsh2um510vsD6pPL7bKnTt3mulR0x2JsECrUXxOd3rVgpMqIwYwg1hek0nvGMu5kMmT72p53OgXyq4IrZyLCLKffvppE6DHXSzMdyy/BmJSixDedkFhredBLVfsK6pPL7bKyZMnm57sfDZIwneNYod3p9eq0TP9+eefNz3VUW8ZjRM3PdsO0VcPjxv1iHpofkElRKcTrMR2ymcYjMZtnt+GoP3qq682PddtPdn80st7eEGhZhH7nurTi63CzvPgwYPtnykj4aBX604VO3ytn0/rj9pKaqw5gee9Z4QDTuScvFUXjxurQ50zv3jGNogAnP+COk3jefR2j8L3kzKOa9eubZdyWK6lRcS+p/r0Yqtcvnx5x0EsGiOP1Cj9jBLSXrC2xv1doMeLi6gIB3GxUzT+7MyftccFAK1WbCvNh/2f0BoTrNDoGaaxfBTuSy8wnNQihMdz+K7xHabRCeR3TMsw7rzS1TlFi+vFET3twY5GyG6bLbIG6eeUwEk53S/yxv2LiIur8rBAAODP2IRv/+xcv9hu2q2tHjrCbUywwv4fITjWZTSWjeo1poeZUsR4bvp8erl5D4bJi/DO56D5ndIqpft3W1MderUlCNbUaW9tbQ2X1MkdXeN0uX9w0RUhIA8WlIuw7JNPPnGIrh7par9YB4Riwm2sk1H10NM06p8JzONEbzhtVH21JM2qF0d0DpQ5ykmibrs26QFeynWxf3ABI0OD5WNg06PHhY9cAGnNZ/8sul/UZtwFhZRzjOsR5pfEvPyprbVdUEgYj/fgfamH9vsgaRWqPaIzykg0Dpzp7WiOOqI+mnf/YLQChuBjVIK8RITAzXICuEP09Vdsz9pLEtjHoveXC/oIszHByiwXFDIZyyjUWR84cGD7NeI5eSmHFxRKqlm1SZDykJhmfVTrKmjzXunrLlqakr6WlJt1/6D0g0lkCB1MKpM+nwBC8Bg3bq/64euvv97erkePHq3ygjrCLL/Qpb3I0/Q6tzWe+8EHHwxfuV1aziFJfVR9Erx582ZzUCZ0562r2SEZpzt0MWxgejKRctPuH4QMhujjz+BtQ/RNGklB/UEpHL9IxfZ96qmnBkeOHOl8+066oJALasf1CvO4dD8c1SKER092OsEK70tz35W0CXqRBEvOfJW/dvRuLxLi0xOOlJu0fxCG+DM85SFpbyE/s4z7auzt1Hzef//95i8VhOt039izZ8/g5ZdfHnz33XfDR45HcKXFdNsXL15sgi3lGfGaky4oZB/jl7tRGGs6RvaIfTMmWCGkR4iOCVa8EFfSputNEowRR9LGQb4EXneW8pFxvTzaXD/88MNMIyQQtv7+7/9+1wWO9GbzOgSg2mt3NT3qnM+ePTt45plnBk8++eSObR6NsE1P9/Xr14fP2o3yCx4bvchxQeCsLQL4pJ7mKOfwWgBJmqwXSZALH9tODLSuEeApH5kFJ6i2z0bT5hr3C9g0jeBNyKI+257B9UJ5xhtvvNH0Yo8K2dG4n32h7bjEfjFp5kLujxAey0aNDe1+Jknd6kUSTE8aeesatd+LKvn51B/zBm3+NM+f4xlhxF7D9UOY/bu/+7uJATttPJbe7fPnzw9f5VfpWNM09jsapSMEaIbWI0RP6qmWJHWvF0nw1KlTrbNAdhGKU/Sc06O9qPSkp801T9CmjIAh+rS+0tFFZmmEbUYj8ZcvSeqPXiTBCxcuNC0dQzvKSbrCRZG8ZhfSk6M21zxBm+dovdCDzS9P9DxzAeG4UrNRjZDNRY3W6EtSv/QiCbadeKJ1gZCd1z/OWqed6vrzqZ8M2puNcE04pkY6n2Ao2jTlI9RxU8/tZCyS1D+9Cdrp+NnRWL6oGDc7b4sMKZi+jjaXQXtzXb16tfUiRUYEYWQPps/n2MNx5vjx47uG9qMRwiklYmQSy0UkqZ96kQRHlXR0VerRtfRkqc1l0N5cDMUY40zTm03ApnebMa4fPnw4fNRj9FS/9tprO8I2IZuRRhhjW5LUX9UmwWlCtEFbNTNor5+ot2Y0j3GTBtED/e677zZ12Tx+UtkHjz99+vT2fkA4//jjj4f3SpL6qtokyMnmwYMHw1u7cR+PqVGcLGv9fFoOg/Z6oAeanui83pqLGruum479gJFJJEn9V3XQnqbVqPbPp+V46623duwLkxqlBgasOjDmNDXUjGdOTXXbbIu/+c1vigVtSdJ6MGgXUPvnU3lMv04QYx/Yu3dvUxYQ3D/qQ2DmwkRKPZ577rmRQ/CxnPvfe++9IkPtxftIktZD1UH75s2bzQQybY37aj0hxcnSE+ZmotTgyJEj2/sA012nPZ/uH3UgKFMScubMme3RQNJtQ2M5pSIxSsj9+/eHzy4j3leStB6qPaIzfN8k0zxmFdITtTYLgZrh2mL7E7jzUSbcP1aLqe0JzjEaSLo9aFEqQr08QXyZk8TEZ5AkrQeP6AWkJ21tDkaOOHXq1Pa2p3SEEpKc+8fqfPbZZ4N9+/bt2Aa0KAmhdIQSkq5rr6cVn0eStB48oheQnsC1ORjzmLDGdqdXlElL2rh/rE5MJBOlIlzsSEkIFz/WwP1CktaLR/QCDFKbhwAXNb6E7XETjbh/dI/aaQIz5R5tf0VIMa5128QxNXC/kKT14hG9AIPUZqE3lJ7R2OaUj+RTZk8aU9vxs2cTo4Qw+kc+Sgg/L7Ouukvxf5AkrYfeHNEfPXq0a+SR33/w/4b31iVOlp4w1x+B7vDhw9vbmwsh2+p7Rw0XF437NR7r+saNG2NHCWEscqYzz3/R6Yv4f0iS1kMvjuhMtZ6eTKMZtLVKBGqG7ottzcWPNZYj9BklIZ9++un2KCHUV6ffLxrLaGyLv/zlLyu7kHFe/rVDktZXL5Jg28mHZtDWKjEJDZPRsJ0J2d9///3wHs2Lnujbt283JSH0WI/6S8DBgweb0UPefvvtppf7559/Hr5C//jXDklaX71IgtS8UjqSM2hrVT744IPtEUYIfZcvXx7eo3nQC/3P//zPTekH6zP9DtFiOeH74sWLTRjva3mIJGlz9CIJXrhwoWmUkKTNoK1VuH79+nYv5DPPPFPtxEl9QngmTKffnbwk5Keffho+WpKkfuhFEkxPvmkzaGvZ8hFG3njjDXtWO8CQfJTf8AvMupSESJLUm6BNr2HeDNq/Onny5I73jcYQaLOK1+LfSRi7ON5ra2truPQxbsd9PC7HZ4v7aYwkk0r/T2zvVWPUCy7Ki8/0yiuvGATHYN0wZjWzLdJb/fHHHw/vaceFpPwi4y8ukqR10YugTZlIG4P2TgTXNBxHCJ4lbBNoY33zvHEBl8fF/RGqU9yO8MxnybdjW/gOPG+eXxJKIfwxbFxs15dfftlShhaE5WvXrg1ef/31puyDkUJindFbzSgikiRtil4E7VEM2jvlQRt8hml7gwm3+Wfm9fKe5sBj0/vSMJ2GcORBfFKQHhfCV+Hs2bNNPTb/B0cY2YkLE6mxpqSGixXzWmsay9966y17qyVJG6XaoE3Ai9CYn7SjGbR3agva3Cbwcl/6ufJGMM7DMbid90SjLZSnz297Ho+PYM798d65eG1a23svG6H/wIEDzefh39p+CVi2KAmhjnrUKCE0erAZmYWh+tj/DNmSpE1TbdBmSD8a2k7iNIP2TnnQJqTyGaYNqwTIPES2LUNbqE+X8S+3U+myqOdu+4xprfcq1mPqu+++Gxw6dKj5DPRo07O9iSiTYeQPRgDJS0KixWyN1LGzz1BvLUnSJqs2aKfyXtZg0N6JEJu+N22WHuFlBu1U9GCnATvF9m/7DKVRT5yOMNLnqb3nFbNf0mvdVhJC4CZgM3vhV1995cyYkiQlehG0RzFo79QWfgP3pZ8rbwRyWv5LTVsJCBYtHcnx+FH3sTz/XKVRHnH06NHt9UMvLaOOzKuv02xTe51/1igJYTQRSkj6NuW5JEnL0ougzayQEQSjMROfQXuncUF7GgTa/PncHhWA+f+lvdD0Oke45t+0Fzq/GDJHkB7Vo837L7NHm15rxseObUiv9qKjZcQEN6Ma99coxremJIT1wHa4e/fu8F5JkjROL4I2IawtnBi0d1o0aIN1HeUdhOVxPclpmCYM5/9fbkd45nUihOd4v1H3YdH/06z4rDHCCPXZ1Gl3KfaNfH0tC7XTbLcYE/z8+fPDe9pRDmJJiCRJs+tF0CYM0IMdYS0CoEH7V4TR9H0jLM8jXisPuKzz/P9EYIv3zHukoxeblvZIp8vz+5C+Jm1UT3cJ7GcxikapEUbS/9syUNrB/kCpByUfee86ddaLlMVIkqR2vQnaafkIwevBgwcGbXWKsbEpk2C77d27d3D69OnhPd1axv5BcObixDNnzmyPBpK+L43lhOwPPvhg+CxJktSlXiRBelL5Ez4Y8i+CgkFbXWH4OmZ7jO3GSBulLvIrtX9QR04PPCUhMRpI+l40AjfLCeAEcXuyJUkqpxdJ8M6dO4MLFy40P9OTHWHboK0uMMLIK6+8sr3NDh8+XDSAdrV/cNEmJSFMCEOAHnXBZYwSEhPHOEqIJEnLUX0SJFiPqtE1aGtRbSOMlJxohQDfxf5BDzzDD44qCWG5E8dIkrRa1SZBarLj4jsaP7MsZdDWot5///2mt5dtRc/v9evXh/d0j3BMb3m6f7BfzzMJDr3T6es4cYwkSfWpNgnmI0/Q8iHgDNpaxNWrV7d7hAnbJS8KZDzqI0eODJ566qkd+8eePXsGb7311o5yDn6mF3pcAKdnnN53J46RJKle1SZBhpajFpv6bBo/58PNGbQ1r5iIJbZTyZkZv/766yYUE6rTfYP25JNPNst///vfN8Gfz0HPNL3rBPB5erslSVIdqk2ChJC0NjvGXk4ZtDUPyiroXY5tdPz48WK9wYRnxuPOe7LbGqE7vU1v+6IzUkqSpNWpOmjn0mWOo615EKgJ1rF9CNyl6pkpf6K0Iw/Qk9r+/fubXm0mz5EkSf1VddCe1AzamgVlGOk47JSOUEJSAsPopfvBLI0x4623liSp/wzaBaSfUfVIRxihLIOyjlIIyn/4wx+mKhmJ9swzzwz27dvX1HRLkqT+qzpoUx4yiqUjmgXD9sWELoRtQndp9KAzfN80YZuQzcyUpXrYJUnS8lWbBPOh/NoYtDUNhspj1I/YJpSPLGM0D3q1GUXk6aef3rFP5I1RRxhfm3G2JUnS+uh1EjRoaxLGm04niSk5wkgqn5yGME3Pdt67zW0+U8kp3yVJ0moYtAtIg5RWh0B94sSJ7W1Bacayeo3T96UenBKSf/3Xf90xdjfttdde88JHSZLWlEG7gDRIaXVOnz492Lt3b7MdCLjff//98J7yzpw509SC5xddUsaS7h9OSCNJ0voyaBeQBil1j7rndB3njfuZTj1GGDl48ODSx6Sml/rGjRutY3Snn1WSJK0vg3YBBqmyYvSQUY2ATbjmZ0bzoGyjJulnlSRJ68ugXYBBarnSdc2U5ekII2+88UZ15Rnx2eIzS5Kk9WTQLsAgtVyxrhm549ixY9u3X3nllcHPP/88fFT3Pvvss8Hbb7898wWW8flokiRpfRm0CzBIdY+a52vXrg2uXLmyq8W6Tkf0KDnCCOGdOnBmceS9CPeziM9IkyRJ66s3Z/o7d+40k9ikzaC9Od55550d63VS+/DDD4fP7BalKUePHt1+n/379zcXXk4yzQWckiRpvfQiCXIxW1s4MWhvjklBNW/0dHeNadzT+m960P/85z8P7x0v/WyjmiRJWi+9OLsTQpg2m8CdNoP25lhl0OZiynfffXfHaCdHjhyZaVzuSSOlcL8kSVovvUiCFy5cGDx69Gh461cG7c2xqqDNBZbM3sgwgbwu/zLrY9v42JIkSaleJEF6s0+ePGmP9gZbRdBmFsfDhw9vv+YLL7wwOHv2rFOmS5KkqfQiCaYBKm0G7c2x7KBN7XVa7jFLPbYkSRJ6E7TzEUccdWSzLCto01tNrzW91/Fas9ZjS5IkoRdJ8N69e8OfdjJob44//OEPO9brpDZP0GbcbeqvrceWJEld6G0S5OJIg/ZmoJeZ8arT9TquPfXUUzMH7e+++66Z5CZew3psSZK0qF4kwVu3bu0IUtEM2uuPoPv666834Tldr5Pa7du3h68wGT3ZBw8e3H6u9diSJKkLvUiChw4d2hGiohm01xtD6x0/fnx7XT777LODf/zHfxz827/9WzMiSLS4P27POvX6t99+O3juueea17AeW5IkdaUXSZAARKnI5cuXt8fTpm7boL2+CMvp0HovvvjiyKnOu1jXN27cGFy8eNF6bEmS1JleJEHG0GaUkQcPHjS925cuXWomsek6aBPWeJ9FRfBbNPxtqh9++GFw9OjR7XVIKcfVq1eH9+7mupYkSTXqRTohWEeQIghHsOoqaNM7Hq9p0F4tLkqkfCPWHz9//fXXw3sfmzTUH/dLkiStWi+SIOUi9GaHO3fuFBlHO3rOF5WGPk2PXuu0Hp9ebXq3c+lEMm2N+3PUezMSyd27d4dLJEmSyupNEiRsM/pIBOESNdrzBu1xPayaDn+1oA471hv12aMuapy1R5sLJKPem/fgtiRJUmm9SIL0YKc9nSB01xK0x/Wwary//e1vg/Pnzw8OHDiwvc4YaYQe6FFm6dGmlzx9PD8btCVJ0jL0IglGAI5a6mDpSL8Rst96663B888/36yrvXv3NmNmzzJJDPXbbeua1z537tyOXnImpKEGXJIkaRl6kQQJSVGjzc+UkVBqYNDuL8L0a6+91oRr1hNhm9A9S8hmuMd0Ipt4Lr3hvHZMpU6jl3zW8bUlSZIW0YskSKCKwJQ2g3Y/5RPRMFkM5SP0Qk/r/fffb5735JNPbr8Or0lJUTr+NlOpU7M9S4CXJEnqQi+SYPRgR3iiURZg0O4fepWPHTu2vX6Y+nzURDRtCOOnT5/e0VsdjdCdBm+nUpekfuCczjk4xfk4XzYJj6fDZRa8D+8vldCrJEjgpk57a2urud1V0Ob10sC26BcufS39qm0iGv5aMa0oN0nLRUY1Lnp0KnVpOfgr1c8//zy8VV7bd57OGJQITXGO4Pyzjr799ttm+NO8ffXVV0v5ayDrl4BMS9exQVvroNokyEFtkq57tLuSHvz12DQT0YzD1Oj0hE8Tsmn0lM/y+pLmc//+/eZai/379y/tOgi+43nojYBl0J7Nl19+OdizZ8+OvwZGY9kyJgBjm0WLX5jAbbYr25PPk4Zu7ovPGcvjcTS2Vfpc9o28U63kL2dSqDpo09sZX768cZ9Bux+uX7++Y3hGRv9om4hmFE7enMinDdk0Hvv0008btqWC+KsR320CGd85foGe5bs9L77jeeglNMX5IQ1N6XEhXZ6GrjTAEcjyx8dj0xLGvOc1lqdBsQ/ee++91pAd7be//e3wkeWw/lnHsZ5DrNfooWZ7sH7zx8W2B68Vj4+gHdL72H68Bq+V7zNSl6oO2pOaQbt+HADTcazHTUQzCn/W5LnjTgZtjRM/9dySuscY9YwWlH4v6RllSM3Sv+DyXnnQjmVpaOLfCGARzuJ56c8R1NLwBYIZy+O58boRxpE/h58jzPUBQZvPPKqVDtqsP9ZzYB3H+mPdp/exnNuxPWKdp9IwHduvTfoaPMagrVIM2gWkn3GT5RPRvPLKK2MnohmHkzqvxYk8Xb9tjRM/F0syXOAsI5lIm+D6l/+39XuTt//9v/7H8BmP/fGd/976uFEN1G2/fvLV1vvT9rvjR2Y6NrS9RgSqcaGJxxHsIrClInClPdJ5sItgjrjN49PnLDO0cSF5/P9rbidOnBhZ6826yx8f6491mW6n+KUm/ZmWPoafRwVtlsdzohm0VVq1SZDZIG/evNl8MbgIMscyg3adYmSQfCKaRS+Wos6bCyjT9Zs3erH37ds383CB0qb4P3/+pPW7k7f/+f6fhs94/J3+b//1v7Q+Lm8Muxk92lxb8dKB/a2PS9s8QTsNvak0NKVhLBrL2oI22kIfj2sL2hHoeK9VBe0zZ87s+rw1tnFBm/vT9RrrOgJwup3GbbcI1LFd4udYjvS98vcxaKuU6pMggZovDV+E+PIEg3Z9YmSQmIgmepa7unKdC6+iJjRdzzR6uxk3Oz3pSSqHGm1++eX7uOoa7ZCGpjR0IZ43KrDx3LbjR1vQjts8flVBuwurrNFmO/AeOdYf65HG/bHeWc665na6/VjGYzEqaOfbkOdw26Ct0nqVBOMLwYWQfFkM2nWhR4qei/i/07PFwavrnmV6yShD4cSermtKS7jwUtLy8Msvf0WiNnuVo46ENDTxuAhdLI/nRejiXxC6eA73tS2Px3MbaUDMn8PPEe76gFFH8mNp2pgcrBTWbazTVGyr2JYEZm7HdkUE5VHL45epdFukz4n7+TfeRyqhN0kwerZPnTq1/UUxaNejbSKakgdoylDyMbUpLZG0/vi+TxO0I7DRYnkErwjINAJXiBCdLk+DdtwXwRrp+7QFx9r9+OOPI5ukxVSfBDkYpge3aBwADdp14GC8yEQ0KXq/P/roo2ZovklBPWrBN2ldS5Kk/qg2nXAhJGE6QlS0CxcuNBdKwqC9evQiU8MX/19C9rxDe/EnaEpC+DM0r0Wv+DR/it6UdS1Jkvql2nQS4YlG4CZ456OPGLRXa9GJaEL0YqfjbTPLHCOHTCOeI0mSVJOqgzYBm9o3ykfyRh2dQXt1Pv744x3BmNEG5rkQKu/FptErfuXKleEjdmNK4HhsW1vGlMGSJEmTVB206cVuC9k07ps2aEcJSvz7L//yL81FMdGoAee+uD+WxQUusTz9mX8J+23isbR1RE9zGrIJyowEMotRvdiMtz3ptdLntDXulyRJWrVqkyBhdxJ7tJcrLj6MiWho80xEQ5B+4403ZurFliRJ6pv1rW1YoQiPtHXBhDOE43QiGoZanHUiGsI0oTrWD2Gb1521R1ySJKl2Bu0CIkTS1kEXE9EQpOn9pjwkXocSD8pHZnkdSZKkvjBoFxBBktZ3XOD4u9/9bkc4nnUimrZebOq6uRBSkiRpXRm0C4hASeuztoloGG1kWvSE24stSZI2lUG7gAiVtL76/vvvF56IhpAdz6em215sSZK0SQzaBUS4pPURgTot9SBwzzMRDeNZP/vss00v9rvvvmsvtiRJ2igG7QL6HLQpDUlDNhPRzNsLzYgkX331VVOCIkmStGkM2gX0NWjnE9FwEaTD7kmSJM3HoF1A34I2JR1nz57dNRENFzNOwqgks46lLUmStAkM2gX0KWjHRDRcrMjnnXYiGmaDPHPmzODgwYODQ4cO2fMtSZKUMWgX0JegHcPvxWdlIhp6tiddtPjNN98MXn755e3nccEjtdiSJEn6lUG7gAigtFrNMxFN2osdz2OM7NOnTzuiiCRJUsagXUCEUFqNGEVk1olo7t69u+M58TxmfZQkSdJuBu0C0jBam1knoqFWmzGw09FI6MWm5MS6bEmSpNEM2gVEIKXVpG0iGoL3KPRiHz58ePtCyXiOvdiSJEmTGbQLiFBKq0U+EQ1lIKMmomnrxd63b59TqEuSJM3AoF1AhFNaDbjIMZ+Ihosh2xCkjx8/vqMXm+d+9NFHXvAoSZI0A4N2ARFQaasUE9EwbF98nlET0fBYwrS92JIkSd0waBcQQZW2KpR/MPFMOhENE9O0TURD8CZQE6zjc9uLLUmStBiDdgERVmmrkE9Ew9Tq4yaiYWzseKy92JIkSd0waBcQoZW2bAy5l09Ec/78+eG97ei5ZhKaF1980V5sSZKkjhi0C1hV0KYX+siRIztC9qSJaAIXRzoutiRJUncM2gWsImj/8MMPuyaiuX79+vBeSZIkLZtBu4BlB+1pJqJh8pnbt28Pb0mSJKk0g3YBywzabRPR/Pjjj8N7H9dsc2EkZSQvvPDC4K9//evwHkmSJJVk0C5gWUF70kQ0V69e3RHCn3766cGHH344vFeSJEklGbQLiGBLK4FRQc6dO7djIpoTJ05sT0Tz888/N0P2MYpI3E8gHzfEnyRJkrpl0C4gwi2ta/lENHv37t0xEc0333wzePnll3d8Bi+MlCRJWj6DdgFpyO0SPdX5RDSnT59ueqmjF5vxsOP+/fv3N4932D5JkqTlM2gXEEGX1hXCMjM2xuumE9GM6sW+cuVKc78kSZKWz6BdQBp4u8AFjm0T0VAu8u6779qLLUmSVCGDdgERemmLYiKatLf60KFDTb0142IfPnx4u1abRgC3F1uSJKkOBu0CIvjSFtE2Ec3NmzebXux0WL99+/Y1ZSVMwS5JkqQ6GLQLiABMm9fly5d3TURz69atwfHjx3f1Yn/00UcO2ydJklQZg3YBEYJp8/jggw921F0fO3asqdO+ePHi9jJ7sSVJkupm0C4gwjBtFpMmomFqdXqwn332WXuxJUmSKmfQLmCeoM0IIm+99daOiWhee+217YloArfzZZIkSaqPQbuAWYN2TERDuOY56UQ0kiRJ6ieDdgGzBG3KQtKJaCgLYUp1Q7YkSVK/GbQLmDZoc4EjY2HHY5966qnB008/3YRtarUlSZLUXwbtAqYJ2vlENE8++eT2z4RtxsqWJElSfxm0C4jATGvDRDTplOppyGZUEUK2pSOSJEn9ZtAuIEIzLZdPRBON0UYoI2FqdUmSJPWfQbuANEBfv359uPTxRDQvvvjijvtp0YvtsH2SJEnrw6C9IEo8Pvzww8Gbb77ZNKZIT0M0FzhSi81Mj/yc3kezF1uSJGk9GbSHLl26tB1+t7a2hksnu3bt2o4a62kbPdtnzpyxF1uSJGlNGbR/8cUXX2wPp0fIJghP68qVK7tC9KRGjfY333wzfAVJkiStI4P2Lwi/9+7dG9563LtN+J7GX/7yl11BelyjfOTf//3fh8+WJEnSutr4oE3AJgCn0h7ucSj7oPY6D9OT2qFDh5oZISVJkrS+Nj5o37p1a3Dy5MnhrcfalrWZp2zEZrPZbDabrev23HPPDdOJamLQXiBo0ys9T4+2zWaz2Ww2W9dN9bF0ZIHSEXz22We7dvRxjYlpLBvpRrpeVZbrejlcx8vhel4e1/VyuJ7r5Vb5BTtnOqTfLBdDzlo+8g//8A/DZ2pR6XpVWa7r5XAdL4freXlc18vheq6XW+UXhGrCNdp6uMchaM8yjjaT2qgb6XpVWa7r5XAdL4freXlc18vheq6XW2Vo3glrbty4sf28aRrTsKsbTF3POuVfleW6Xg7Wr+u4PNfz8riul8P1XC+Ddgd+/PHHHe2TTz7Znm79T3/60/by+/fvD58hSZKkdWfQLuThw4eDn376aXhLkiRJm8agLUmSJBVg0JYkSZIKMGhLkiRJBRi0JUmSpAIM2pIkSVIBBm1JkiSpAIO2JEmSVIBBW5IkSSrAoC1JkiQVYNCWJEmSCjBoF3Dp0qXBE0880bStra3hUnWBdfrFF18Mb/2K9RzrnPWv+aTrkZbvv67nbuTrOed67h7HjXPnzg1vPeZ67s6tW7e21yXt3r17w3tczyWcPHly1/p0PdfJoN2x9GAeO70Wx0E7DiBtQZvlcWDnANP2GE3GwTuwHvP91/XcjXw95ydF13O34viRB23Xc3fyfTjleu5O/ELTtg5dz3UyBXYs3dHhzt4tAkq+PrmdnkD9BWc+HMBTsR5jf3Y9d4P1lmK9pyHF9dw91ifrOF2vrufucIzIjx/B9dwd1jPrLj+GwPVcL7dCh+JLkMp3fi2mLWizfvNlbIf0Fx7NJz2ou56713YydD13K46/edB2PXeHdcm6y/dluJ67E+sy1rX7cz8YtDvEb/Tpn4TRtkzzawvaLMt7U9qWaTYcoNOeVtdzt0aFE9dzdzhWRNDIg7bruTvxy3iEwPQY7XruRvxSHsfkuB3r2vVcL4N2h9ih2bFTbcs0P9alQXs50lAC13MZrMM0bLueu0HATo8VBu3lYL2zP0f4dj13g/XFekuxT8cy13O9DNodigNMigN9Hlg0Pw4cedBm/ebL2A7Rk6XZsT7z9ed6LiN6piKYuJ67wXpkvbW1uN/1XAbrNtaj67kbbUE7XeZ6rpdBu2Ps2HHCBL9x5ju/5tcWtLkdf05DBBfNh4N32z7rei4nPW64nstgnRJGguu5HNaz+3O3Yr3FegXH6li3rud6uRU6lu7s/Cbpjt6ttqCN9ADU9pu9ppMeuEN62/XcvfwECddz91jHadCG67l7bb+ou567wbpL92HWa9pj7XqukymwAA7o7PDpTq/FsB5jndLSgw3S+/PQoumk+23aOHEG1/PiWJ/p+m07Gbqeu8d69LjRvfzY3LYeXc/dYR+OdZkem+F6rpNBW5IkSSrAoC1JkiQVYNCWJEmSCjBoS5IkSQUYtCVJkqQCDNqSJElSAQZtSZIkqQCDtiRJklSAQVuSJEkqwKAtSZIkFWDQliRJkgowaEuSJEkFGLQlbawvvvhi8MQTT4xtPAaXLl1qbt+7d6+5vQxbW1vNe86L5548eXJ4a7xz584Nbt26NbwlSeqCQVvSxiJER3Dm3wjXsYzguaqgzXsv+n6zBG3wWP6fkqRuGLQl6RdtQXtVoid72T3Mq3pfSVpXBm1J+sW4oJ2WmBBC08fSA0zZBT9H7zH/prdD9FLH80aJ3vMwz/vFMhriObT0c+Shmsfln1uSNB+DtiT9YlzQRgTXCKYRhuPxaZClZzhux+Pj9aMUJb0vx308PzXv+9FC3OaxcX8equOXCu6XJC3GoC1Jv0iDaVvIHBW0+Te9HUE6D75xO16b12NZLj5Hft+s75f+f0LcJpjH/aOC9qhfAiRJ0zNoS9Iv0mAaYTg1b9DOb6ctD7lYNGjH7WmDdno/ImjH60iS5mfQlqRfLCtoT+opjgsSDdqS1H8GbUn6RemgzfO4nfZi52E68LhVB+22dSBJmo1BW9LGi9Catgi0iPAZLQ2ptPz5EXqjEWyRPy6W5+JxYZ73i18MaDw+fQz35fcHHpf+MiBJmp9BW5IqQ1AmAE8qM+naqt5XktaVQVuSKhSlJqN6vUvIe7clSYsxaEtSpaKHeRkoGbEnW5K6ZdCWJEmSCjBoS5IkSQUYtCVJkqQCDNqSJElSAQZtSZIkqQCDtiRJklSAQVuSJEkqwKAtSZIkFWDQliRJkgowaEuSJEkFGLQlSZKkAgzakiRJUgEGbUmSJKkAg7YkSZJUgEFbkiRJKsCgLUmSJBVg0JYkSZI6Nxj8f592BaU77xG1AAAAAElFTkSuQmCC" /></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>The safety and efficacy of Abstral have been evaluated in patients taking the drug at the onset of the breakthrough pain episode. Preemptive use of Abstral for predictable pain episodes was not investigated in the clinical trials.</p><p>&nbsp;</p><p>Fentanyl, in common with all &micro;-opioid receptor agonists, produces dose dependent respiratory depression. This risk is higher in opioid-na&iuml;ve subjects than in patients experiencing severe pain or receiving chronic opioid therapy. Long-term treatment with opioids typically leads to development of tolerance to their secondary effects.</p><p>&nbsp;</p><p>While opioids generally increase the tone of urinary tract smooth muscle, the net effect tends to be variable, in some cases producing urinary urgency, in others, difficulty in urination.</p><p>&nbsp;</p><p>Opioids increase the tone and decrease the propulsive contractions of the smooth muscle of the gastrointestinal tract leading to a prolongation in gastrointestinal transit time, which may be responsible for the constipating effect of fentanyl.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fentanyl is a highly lipophilic drug absorbed very rapidly through the oral mucosa and more slowly through the gastrointestinal tract. Orally administered fentanyl undergoes pronounced hepatic and intestinal first pass effects.</p><p>Abstral is a quick dissolving sublingual tablet formulation. Rapid absorption of fentanyl occurs over about 30 minutes following administration of Abstral. The absolute bioavailability of Abstral has been calculated to be 54 %. Mean maximal plasma concentrations of fentanyl range from 0.2 to 1.3 ng/ml (after administration of 100 to 800 &micro;g Abstral) and are reached within 22.5 to 240 minutes.</p><p>&nbsp;</p><p>About 80-85% of fentanyl is bound by plasma proteins, mainly a1-glycoprotein and to a lesser extent albumin and lipoprotein. The volume of distribution of fentanyl at steady state is about 3-6 l/kg.</p><p>&nbsp;</p><p>Fentanyl is metabolised primarily via CYP3A4 to a number of pharmacologically inactive metabolites, including norfentanyl. Within 72 hours of intravenous fentanyl administration around 75% of the dose is excreted into the urine, mostly as metabolites, with less than 10% as unchanged drug. About 9% of the dose is recovered in the faeces, primarily as metabolites. Total plasma clearance of fentanyl is about 0.5 l/h/kg.</p><p>After Abstral administration, the main elimination half-life of fentanyl is about 7 hours (range 3-12.5 hours) and the terminal half-life is about 20 hours (range 11.5-25 hours).</p><p>The pharmacokinetics of Abstral have been shown to be dose proportional over the dose range of 100 to 800 &micro;g. Pharmacokinetic studies have shown that multiple tablets are bioequivalent to single tablets of the equivalent dose.</p><p>&nbsp;</p><p><u>Renal/hepatic impairment</u></p><p>Impaired hepatic or renal function could cause increased serum concentrations. Older, cachectic or generally impaired patients may have a lower fentanyl clearance, which could cause a longer terminal half-life for the compound (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety pharmacology and repeated dose toxicity data reveal no special hazard for humans that is not already covered by other sections of this SPC. Animal studies have shown reduced fertility and increased mortality in rat foetuses. Teratogenic effects have, however, not been demonstrated.</p><p>Mutagenicity testing in bacteria and in rodents yielded negative results. Like other opioids fentanyl showed mutagenic effects <em>in vitro </em>in mammalian cells. A mutagenic risk with therapeutic use seems unlikely since effects were induced only at very high concentrations.</p><p>&nbsp;</p><p>Carcinogenicity studies (26-week dermal alternative bioassay in Tg.AC transgenic mice; two-year subcutaneous carcinogenicity study in rats) with fentanyl did not reveal any findings indicative of oncogenic potential. Evaluation of brain slides from the carcinogenicity study in rats revealed brain lesions in animals administered high doses of fentanyl citrate. The relevance of these findings to humans is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol (E421)</p><p>Silicified microcrystalline cellulose Croscarmellose sodium</p><p>&nbsp;</p><p>Magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p><p>&nbsp;</p><p>Store in the original blister package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abstral sublingual tablets are packaged in child resistant blisters of OPA/Aluminium/PVC pockets with paper/polyester/Aluminium lidding contained in a cardboard outer carton. The packaging is colour-coded for each Abstral sublingual tablet strength.</p><p>Pack size: Packs of 10 or 30 sublingual tablets. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Waste material should be disposed of safely. Patients/carers should be encouraged to return any unused product to the Pharmacy, where it should be disposed of in accordance with national and local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kyowa Kirin Ltd
Galabank Business Park
Galashiels
TD1 1QH
UK

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                27 May 2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>